Guadalupe Garcia-Tsao, MD, FRCP

• Anahita Rabiee
• Avlin Imaeda
• Basile Njei, MD, MPH, PhD
• Brian West
• Caroline Falker
• Chirag Parikh
• David Mulligan
• Deborah Proctor
• Dennis Shung
• Dhanpat Jain
• F. Perry Wilson
• James Boyer
• Jeffrey Pollak
• Justin Belcher
• Katharine Henderson
• Lawrence Young
• Loren Laine
• Morton Glickman
• Rajni Mehta
• Robert Makuch
• Sina Nikayin
• Tamar Taddei
• Uyen To

Ascites; Hepatorenal Syndrome; Liver; Liver Cirrhosis; Liver Diseases; Veterans

• Acute Kidney Injury in Patients with CirrhosisNadim M, Garcia-Tsao G. Acute Kidney Injury in Patients with Cirrhosis New England Journal Of Medicine 2023, 388: 733-745. PMID: 36812435, DOI: 10.1056/nejmra2215289.
• Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosisNoureddin M, Goodman Z, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Garcia‐Tsao G, Harrison S, Chalasani N. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis Alimentary Pharmacology & Therapeutics 2023, 57: 409-417. PMID: 36647687, DOI: 10.1111/apt.17363.
• Endovascular Assessment of Liver Hemodynamics in Cirrhotic Patients with Portal HypertensionFerral H, Schepis F, Gaba R, Garcia-Tsao G, Zanetto A, Perez-Campuzano V, Haskal Z, Garcia-Pagan J. Endovascular Assessment of Liver Hemodynamics in Cirrhotic Patients with Portal Hypertension Journal Of Vascular And Interventional Radiology 2022 PMID: 36516940, DOI: 10.1016/j.jvir.2022.12.014.
• Role Of Oral Health, Frailty and Minimal Hepatic Encephalopathy In The Risk Of Hospitalization: A Prospective Multi-Center Cohort Of Outpatients with CirrhosisBajaj J, Lai J, Tandon P, O'Leary J, Wong F, Garcia-Tsao G, Vargas H, Kamath P, Biggins S, Limon-Miro A, Shaw J, Mbachi C, Chew M, Golob Deeb J, Thacker L, Reddy K. Role Of Oral Health, Frailty and Minimal Hepatic Encephalopathy In The Risk Of Hospitalization: A Prospective Multi-Center Cohort Of Outpatients with Cirrhosis Clinical Gastroenterology And Hepatology 2022 PMID: 36328307, DOI: 10.1016/j.cgh.2022.10.023.
• “Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH”: Comment from Hartmann et al.Hartmann J, Dias JD, Garcia-Tsao G, Pivalizza EG. “Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH”: Comment from Hartmann et al. Journal Of Thrombosis And Haemostasis 2022, 20: 2711-2712. PMID: 36271460, DOI: 10.1111/jth.15861.
• Concept of Further Decompensation and RecompensationD’Amico G, Garcia-Tsao G. Concept of Further Decompensation and Recompensation 2022, 523-535. DOI: 10.1007/978-3-031-08552-9_47.
• Preventing Further Decompensation: Consensus Statements of Panel 7Garcia-Tsao G, Reiberger T, Bureau C, D’Amico G, La Mura V, Piano S, Tandon P, Turco L. Preventing Further Decompensation: Consensus Statements of Panel 7 2022, 579-583. DOI: 10.1007/978-3-031-08552-9_51.
• Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based modelRabiee A, Deng Y, Ciarleglio M, Chan JL, Pons M, Genesca J, Garcia‐Tsao G. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model Hepatology Communications 2022, 6: 3324-3334. PMID: 36214066, PMCID: PMC9701481, DOI: 10.1002/hep4.2091.
• Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled TrialsHartmann J, Dias J, Pivalizza E, Garcia-Tsao G. Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials Seminars In Thrombosis And Hemostasis 2022 DOI: 10.1055/s-0042-1757135.
• Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosisBajaj JS, Reddy KR, Tandon P, Garcia‐Tsao G, Kamath PS, O'Leary JG, Wong F, Lai J, Vargas H, Thuluvath PJ, Subramanian RM, Pena‐Rodriguez M, Sikaroodi M, Thacker LR, Gillevet PM. Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis Liver Transplantation 2022, 28: 1831-1840. PMID: 36017804, DOI: 10.1002/lt.26552.
• FRI516 Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosisNoureddin M, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Harrison S, Garcia-Tsao G, Goodman Z, Chalasani N. FRI516 Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis Journal Of Hepatology 2022, 77: s623-s624. DOI: 10.1016/s0168-8278(22)01564-1.
• FRI509 Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosisNoureddin M, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Harrison S, Garcia-Tsao G, Chalasani N, Goodman Z. FRI509 Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosis Journal Of Hepatology 2022, 77: s619-s620. DOI: 10.1016/s0168-8278(22)01557-4.
• SAT496 SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosisO’Leary J, Reddy K, Tandon P, Kamath P, Garcia-Tsao G, Wong F, Lai J, Subramanian R, Thuluvath P, Maliakkal B, Vargas H, Biggins S, Thacker L, Bajaj J. SAT496 SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis Journal Of Hepatology 2022, 77: s887-s888. DOI: 10.1016/s0168-8278(22)02066-9.
• THU494 Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosisBajaj J, O’Leary J, Tandon P, Garcia-Tsao G, Kamath P, Thuluvath P, Subramanian R, Vargas H, McGeorge S, Fagan A, Wong F, Lai J, Thacker L, Reddy R. THU494 Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis Journal Of Hepatology 2022, 77: s339-s340. DOI: 10.1016/s0168-8278(22)01041-8.
• Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory AscitesBajaj J, Fischer J, Yeramian P, Gavis E, Fagan A, Angeli P, Garcia-Tsao G, Adams J, Markham P. Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites GastroHep 2022, 2022: 1-8. DOI: 10.1155/2022/5065478.
• Portal pressure reductions induced by nonselective beta‐blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascitesTurco L, García‐Tsao G. Portal pressure reductions induced by nonselective beta‐blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites Clinical Liver Disease 2022, 20: 1-4. PMID: 35899241, PMCID: PMC9306434, DOI: 10.1002/cld.1210.
• Invasive fungal infections are underdiagnosed in hospitalized patients with decompensated cirrhosis: an autopsy studySaffo S, Jain D, Sanchez H, Garcia-Tsao G. Invasive fungal infections are underdiagnosed in hospitalized patients with decompensated cirrhosis: an autopsy study Gastro Hep Advances 2022, 1: 803-806. PMID: 36160304, PMCID: PMC9497452, DOI: 10.1016/j.gastha.2022.05.015.
• 82: SERUM METABOLITES ON ADMISSION ASSOCIATE WITH OCCURRENCE OF NOSOCOMIAL INFECTIONS IN HOSPITALIZED PATIENTS WITH CIRRHOSISBajaj J, O'Leary J, Tandon P, Garcia-Tsao G, Kamath P, Thuluvath P, Subramanian R, Lai J, Vargas H, Mcgeorge S, Fagan A, Wong F, Thacker L, Reddy K. 82: SERUM METABOLITES ON ADMISSION ASSOCIATE WITH OCCURRENCE OF NOSOCOMIAL INFECTIONS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS Gastroenterology 2022, 162: s-1114. DOI: 10.1016/s0016-5085(22)62677-5.
• Sa1456: SBP VERSUS NON-SBP BACTERIAL INFECTIONS AT ADMISSION HAVE COMPARABLE OUTCOMES IN A MULTI-CENTER COHORT OF INPATIENTS WITH CIRRHOSISO'Leary J, Reddy K, Tandon P, Kamath P, Garcia-Tsao G, Wong F, Lai J, Subramanian R, Thuluvath P, Maliakkal B, Vargas H, Biggins S, Thacker L, Bajaj J. Sa1456: SBP VERSUS NON-SBP BACTERIAL INFECTIONS AT ADMISSION HAVE COMPARABLE OUTCOMES IN A MULTI-CENTER COHORT OF INPATIENTS WITH CIRRHOSIS Gastroenterology 2022, 162: s-1175-s-1176. DOI: 10.1016/s0016-5085(22)63501-7.
• Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global StudyMorales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes J, Cruz-Lemini M, Thursz M, Atkinson S, Sarin S, Kim W, Chavez-Araujo R, la Tijera M, Singal A, Shah V, Kamath P, Duarte-Rojo A, Charles E, Vargas V, Jager M, Rautou P, Rincon D, Zamarripa F, Restrepo-Gutiérrez J, Torre A, Lucey M, Arab J, Mathurin P, Louvet A, García-Tsao G, González J, Verna E, Brown R, Argemi J, Fernández-Carrillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R. Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study The American Journal Of Gastroenterology 2022, 117: 818-818. PMID: 35501978, DOI: 10.14309/ajg.0000000000001704.
• 256: PRIOR PERIODONITIS AND PATIENT-REPORTED OUTCOMES PREDICT THE RISK OF 3-MONTH HOSPITALIZATION IN A MULTI-CENTER CIRRHOSIS COHORTBajaj J, Lai J, Tandon P, O'Leary J, Garcia-Tsao G, Wong F, Vargas H, Kamath P, Biggins S, Shaw J, Limon-Miro A, Chew M, Mbachi C, Thacker L, Reddy R. 256: PRIOR PERIODONITIS AND PATIENT-REPORTED OUTCOMES PREDICT THE RISK OF 3-MONTH HOSPITALIZATION IN A MULTI-CENTER CIRRHOSIS COHORT Gastroenterology 2022, 162: s-54. DOI: 10.1016/s0016-5085(22)60136-7.
• Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?Rabiee A, Garcia‐Tsao G, Tapper EB. Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How? Clinical Liver Disease 2022, 19: 118-123. PMID: 35355838, PMCID: PMC8958249, DOI: 10.1002/cld.1182.
• Ascites and its complicationsGarcia‐Tsao G. Ascites and its complications 2022, 522-531. DOI: 10.1002/9781119600527.ch59.
• Ascites and its complicationsGarcía‐Tsao G. Ascites and its complications 2022, 2024-2043. DOI: 10.1002/9781119600206.ch98.
• Prognosis of hospitalized patients with cirrhosis and acute kidney diseaseWong F, Garcia‐Tsao G, Reddy KR, O'Leary JG, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggins SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker L, Bajaj JS. Prognosis of hospitalized patients with cirrhosis and acute kidney disease Liver International 2022, 42: 896-904. PMID: 35023264, DOI: 10.1111/liv.15154.
• Baveno VII – Renewing consensus in portal hypertensionde Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Faculty B, Abraldes J, Albillos A, Baiges A, Bajaj J, Bañares R, Barrufet M, Benajiba L, Berzigotti A, Bureau C, Calvaruso V, Cardenas A, D’Amico G, De Gottardi A, Dell’Era A, Escorsell A, Fallowfield J, Ferral H, Francque S, Gaba R, Garcia-Pagàn J, Genescà J, Rodrigues S, Gracia-Sancho J, Han G, Hernandez-Gea V, Jia J, Kiladjian J, Krag A, Laleman W, La Mura V, Lens S, Luo X, Mandorfer M, Murad S, Paradis V, Patch D, Piano S, Pinzani M, Plessier A, Primignani M, Procopet B, Rautou P, Rudler M, Sarin S, Schepis F, Senzolo M, Shah V, Shukla A, Tandon P, Tellez L, Thabut D, Thiele M, Trebicka J, Tripathi D, Tsochatzis E, Turco L, Turon F, Valla D, Villanueva C, Wanless I, Yoshiji H. Baveno VII – Renewing consensus in portal hypertension Journal Of Hepatology 2021, 76: 959-974. PMID: 35120736, DOI: 10.1016/j.jhep.2021.12.022.
• The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global StudyMorales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes J, Cruz-Lemini M, Thursz M, Atkinson S, Sarin S, Kim W, Chavez-Araujo R, la Tijera M, Singal A, Shah V, Kamath P, Duarte-Rojo A, Charles E, Vargas V, Jager M, Rautou P, Rincon D, Zamarripa F, Restrepo-Gutiérrez J, Torre A, Lucey M, Arab J, Mathurin P, Louvet A, García-Tsao G, González J, Verna E, Brown R, Argemi J, Fernández-Carillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study The American Journal Of Gastroenterology 2021, 117: 301-310. PMID: 34962498, PMCID: PMC8999152, DOI: 10.14309/ajg.0000000000001596.
• A Historical Overview of Spontaneous Bacterial Peritonitis: From Rare to ResistantHaque LY, Garcia‐Tsao G. A Historical Overview of Spontaneous Bacterial Peritonitis: From Rare to Resistant Clinical Liver Disease 2021, 18: 63-75. PMID: 34745584, PMCID: PMC8555457, DOI: 10.1002/cld.1122.
• Can We Rely on Changes in HVPG in Patients with Cirrhosis?Garcia‐Tsao G. Can We Rely on Changes in HVPG in Patients with Cirrhosis? Hepatology 2021, 74: 2945-2947. PMID: 34569630, DOI: 10.1002/hep.32159.
• O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMESRagazzo T, Garcia-Tsao G, Mazo D, Ziteli P, Oliveira C, Singer J, Carrilho F, Pessoa M. O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES Annals Of Hepatology 2021, 24: 100493. DOI: 10.1016/j.aohep.2021.100493.
• Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver DiseasesBiggins SW, Angeli P, Garcia‐Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases Hepatology 2021, 74: 1014-1048. PMID: 33942342, DOI: 10.1002/hep.31884.
• The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated HepatitisMusto JA, Eickhoff J, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Mathurin P, Garcia‐Tsao G, Schnabl B, Bataller R, Lucey MR. The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis Liver Transplantation 2021, 27: 1382-1391. PMID: 34109723, DOI: 10.1002/lt.26203.
• Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and AscitesYan K, Hung A, Parmer C, Yang H, Jain D, Lim B, Goodman AL, Garcia‐Tsao G. Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites Hepatology Communications 2021, 5: 1507-1517. PMID: 34510838, PMCID: PMC8435275, DOI: 10.1002/hep4.1740.
• Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!Zanetto A, Senzolo M, Campello E, Bulato C, Gavasso S, Saggiorato G, Feltracco P, Farinati F, Russo FP, Burra P, Garcia‐Tsao G, Simioni P. Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet! Transplant International 2021, 34: 1325-1327. PMID: 33932057, DOI: 10.1111/tri.13895.
• Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or DeathChew M, Tang Z, Radcliffe C, Caruana D, Doilicho N, Ciarleglio MM, Deng Y, Garcia-Tsao G. Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death Clinical Gastroenterology And Hepatology 2021, 19: 2182-2191.e7. PMID: 34004326, PMCID: PMC8123528, DOI: 10.1016/j.cgh.2021.05.022.
• 431 SPECIFIC URINARY AND SERUM METABOLITES ON ADMISSION PREDICT THE DEVELOPMENT OF AKI AND NEED FOR DIALYSIS IN HOSPITALIZED PATIENTS WITH CIRRHOSISBajaj J, Garcia-Tsao G, Reddy R, O'Leary J, Vargas H, Lai J, Kamath P, Tandon P, Subramanian R, Thuluvath P, Fagan A, Sehrawat T, De La Rosa-Rodriguez R, Wong F. 431 SPECIFIC URINARY AND SERUM METABOLITES ON ADMISSION PREDICT THE DEVELOPMENT OF AKI AND NEED FOR DIALYSIS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS Gastroenterology 2021, 160: s-775-s-776. DOI: 10.1016/s0016-5085(21)02565-8.
• SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of DecompensationKaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.
• Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter CohortBajaj JS, Garcia‐Tsao G, Wong F, Biggins SW, Kamath PS, McGeorge S, Chew M, Pearson M, Shaw J, Kalluri A, Fagan A, Olofson A, Moini M, de la Rosa Rodriguez R, Reddy KR. Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID‐19: A Multicenter Cohort Liver Transplantation 2021, 27: 1343-1347. PMID: 33427401, PMCID: PMC8014819, DOI: 10.1002/lt.25981.
• ReplyGarcía-Tsao G, Montalvo-Gordon I. Reply Hepatology 2021, 73: 867-867. PMID: 32484955, DOI: 10.1002/hep.31401.
• Sleep Disturbance Is Associated With the Presence of Portosystemic Collaterals in Patients With Compensated CirrhosisBalakrishnan M, Falker C, Conley S, Ciarleglio M, Deng Y, Redeker NS, Garcia‐Tsao G. Sleep Disturbance Is Associated With the Presence of Portosystemic Collaterals in Patients With Compensated Cirrhosis Hepatology Communications 2021, 5: 491-501. PMID: 33681681, PMCID: PMC7917284, DOI: 10.1002/hep4.1636.
• Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver DiseasesNorthup PG, Garcia‐Pagan J, Garcia‐Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases Hepatology 2021, 73: 366-413. PMID: 33219529, DOI: 10.1002/hep.31646.
• Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure‐Related Bleeding in Decompensated CirrhosisZanetto A, Rinder HM, Senzolo M, Simioni P, Garcia‐Tsao G. Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure‐Related Bleeding in Decompensated Cirrhosis Hepatology Communications 2020, 5: 272-282. PMID: 33553974, PMCID: PMC7850311, DOI: 10.1002/hep4.1641.
• SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertensionSaffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.
• Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and DiabetesMontalvo‐Gordon I, Chi‐Cervera L, García‐Tsao G. Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes Hepatology 2020, 72: 1880-1882. PMID: 32294260, DOI: 10.1002/hep.31270.
• Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for InnovationVerna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia‐Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation Hepatology 2020, 72: 1819-1837. PMID: 32740969, PMCID: PMC7435542, DOI: 10.1002/hep.31491.
• Factors associated with health‐related quality of life in patients with cirrhosis: a systematic reviewRabiee A, Ximenes R, Nikayin S, Hickner A, Juthani P, Rosen RH, Garcia‐Tsao G. Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review Liver International 2020, 41: 6-15. PMID: 32998172, DOI: 10.1111/liv.14680.
• Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular MalformationsKim AS, Henderson KJ, Pawar S, Kim MJ, Punjani S, Pollak JS, Fahey JT, Garcia‐Tsao G, Sugeng L, Young LH. Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations Journal Of The American Heart Association 2020, 9: e016197. PMID: 33054561, PMCID: PMC7763373, DOI: 10.1161/jaha.120.016197.
• Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo‐coagulable and Hyper‐coagulable FeaturesZanetto A, Rinder HM, Campello E, Saggiorato G, Deng Y, Ciarleglio M, Wilson FP, Senzolo M, Gavasso S, Bulato C, Simioni P, Garcia‐Tsao G. Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo‐coagulable and Hyper‐coagulable Features Hepatology 2020, 72: 1327-1340. PMID: 32614088, PMCID: PMC8672302, DOI: 10.1002/hep.31443.
• Intestinal Virome in Patients With Alcoholic HepatitisJiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, Schwanemann LK, Ventura‐Cots M, Bataller R, Bosques‐Padilla F, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia‐Tsao G, Kisseleva T, Brenner DA, Tu XM, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome in Patients With Alcoholic Hepatitis Hepatology 2020, 72: 2182-2196. PMID: 32654263, PMCID: PMC8159727, DOI: 10.1002/hep.31459.
• THU137 Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosisZanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. THU137 Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis Journal Of Hepatology 2020, 73: s206-s207. DOI: 10.1016/s0168-8278(20)30921-1.
• AS044 Stage 1b acute kidney injury in cirrhosis is likely due to underlying chronic kidney disease and would be more appropriately re-classified as acute-on-chronic kidney diseaseWong F, Reddy R, Tandon P, O’Leary J, Biggins S, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas H, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. AS044 Stage 1b acute kidney injury in cirrhosis is likely due to underlying chronic kidney disease and would be more appropriately re-classified as acute-on-chronic kidney disease Journal Of Hepatology 2020, 73: s35-s36. DOI: 10.1016/s0168-8278(20)30623-1.
• SAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trialBajaj J, Yeramian P, Gavis E, Fagan A, Fischer J, Garcia-Tsao G, Angeli P, Smith D, Adams J, Markham P. SAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial Journal Of Hepatology 2020, 73: s718-s719. DOI: 10.1016/s0168-8278(20)31895-x.
• Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With CirrhosisBajaj JS, Reddy KR, O'Leary JG, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, Fagan A, White MB, Gavis EA, Sehrawat T, de la Rosa Rodriguez R, Thacker LR, Sikaroodi M, Garcia-Tsao G, Gillevet PM. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis Gastroenterology 2020, 159: 1715-1730.e12. PMID: 32687928, PMCID: PMC7680282, DOI: 10.1053/j.gastro.2020.07.019.
• Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated CirrhosisD’Amico G, Abraldes JG, Rebora P, Valsecchi MG, Garcia‐Tsao G. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis Hepatology 2020, 72: 1029-1042. PMID: 31837238, DOI: 10.1002/hep.31070.
• #LiverTwitter: An Emerging Tool for Liver Education and ResearchMikolajczyk AE, Ufere N, Breu AC, Parikh ND, Garcia‐Tsao G, Tapper EB. #LiverTwitter: An Emerging Tool for Liver Education and Research Hepatology Communications 2020, 4: 1229-1233. PMID: 32766481, PMCID: PMC7395060, DOI: 10.1002/hep4.1539.
• 1002 ACUTE KIDNEY INJURY IS ASSOCIATED WITH REVERSIBLE PLATELET DYSFUNCTION IN HOSPITALIZED PATIENTS WITH DECOMPENSATED CIRRHOSIS.Zanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. 1002 ACUTE KIDNEY INJURY IS ASSOCIATED WITH REVERSIBLE PLATELET DYSFUNCTION IN HOSPITALIZED PATIENTS WITH DECOMPENSATED CIRRHOSIS. Gastroenterology 2020, 158: s-1301. DOI: 10.1016/s0016-5085(20)33914-7.
• 458 ARTIFICIAL INTELLIGENCE TECHNIQUES DEMONSTRATE BETTER PREDICTION FOR 90-DAY READMISSION AND DEATH IN WOMEN THAN MEN WITH CIRRHOSIS.Saboo K, Hu C, Reddy K, O'Leary J, Tandon P, Wong F, Garcia-Tsao G, Kamath P, Lai J, Biggins S, Fallon M, Thuluvath P, Subramanian R, Maliakkal B, Vargas H, Thacker L, Iyer R, Bajaj J. 458 ARTIFICIAL INTELLIGENCE TECHNIQUES DEMONSTRATE BETTER PREDICTION FOR 90-DAY READMISSION AND DEATH IN WOMEN THAN MEN WITH CIRRHOSIS. Gastroenterology 2020, 158: s-1279. DOI: 10.1016/s0016-5085(20)33859-2.
• Su1696 SPLEEN STIFFNESS MEASUREMENTS (SSM) IN THE IDENTIFICATION OF CLINICALLY-SIGNIFICANT PORTAL HYPERTENSION (CSPH) IN PATIENTS WITH COMPENSATED CIRRHOSIS.Ortiz G, Palumbo C, Sayyar M, Balakrishnan M, Mohanty A, Garcia-Tsao G. Su1696 SPLEEN STIFFNESS MEASUREMENTS (SSM) IN THE IDENTIFICATION OF CLINICALLY-SIGNIFICANT PORTAL HYPERTENSION (CSPH) IN PATIENTS WITH COMPENSATED CIRRHOSIS. Gastroenterology 2020, 158: s-1385. DOI: 10.1016/s0016-5085(20)34131-7.
• Su1678 IMPACT OF RACE AND ETHNICITY ON OUTCOMES IN A MULTI-CENTER NORTH AMERICAN COHORT OF INPATIENTS WITH CIRRHOSISBajaj J, O'Leary J, Tandon P, Wong F, Garcia-Tsao G, Kamath P, Lai J, Biggins S, Fallon M, Maliakkal B, Subramanian R, Thuluvath P, Vargas H, Thacker L, Reddy K. Su1678 IMPACT OF RACE AND ETHNICITY ON OUTCOMES IN A MULTI-CENTER NORTH AMERICAN COHORT OF INPATIENTS WITH CIRRHOSIS Gastroenterology 2020, 158: s-612. DOI: 10.1016/s0016-5085(20)32229-0.
• Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosisZanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis Digestive And Liver Disease 2020, 52: e13. DOI: 10.1016/j.dld.2019.12.031.
• Author response to Letter to the Editor: ‘Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient’Ortiz GA, Sayyar M, Garcia‐Tsao G. Author response to Letter to the Editor: ‘Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient’ Liver International 2019, 40: 990-991. PMID: 31749290, DOI: 10.1111/liv.14302.
• Gastroesophageal Variceal Bleeding ManagementZanetto A, Garcia-Tsao G. Gastroesophageal Variceal Bleeding Management 2019, 39-66. DOI: 10.1007/978-3-030-24490-3_4.
• Prophylactic Antibiotics in Cirrhosis: Are They Promoting or Preventing Infections?Garcia‐Tsao G. Prophylactic Antibiotics in Cirrhosis: Are They Promoting or Preventing Infections? Clinical Liver Disease 2019, 14: 98-102. PMID: 31632658, PMCID: PMC6784797, DOI: 10.1002/cld.819.
• ReplyHagerty D, Garcia-Tsao G, Bosch J. Reply Hepatology 2019, 70: 1079-1080. PMID: 31034095, DOI: 10.1002/hep.30681.
• Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosisSayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia‐Tsao G. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis Liver International 2019, 39: 2061-2065. PMID: 31365178, DOI: 10.1111/liv.14203.
• Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic HepatitisLang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Lucey MR, Louvet A, Mathurin P, Garcia‐Tsao G, Ho SB, Tu XM, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis Hepatology 2019, 71: 522-538. PMID: 31228214, PMCID: PMC6925657, DOI: 10.1002/hep.30832.
• ReplyWong F, Reddy KR, O’Leary J, Garcia‐Tsao G, Kamath PS, Bajaj JS, for the Study of the Liver F. Reply Liver Transplantation 2019, 25: 1586-1587. PMID: 31344749, DOI: 10.1002/lt.25612.
• Su1527 – Potentially Preventable Readmissions and Complications in Hospitalized Patients with Hepatic Encephalopathy in a Large Multi-Center CohortBajaj J, Tandon P, O’Leary J, Wong F, Garcia-Tsao G, Biggins S, Kamath P, Thuluvath P, Lai J, Vargas H, Subramanian R, Maliakkal B, Fallon M, Thacker L, Reddy K. Su1527 – Potentially Preventable Readmissions and Complications in Hospitalized Patients with Hepatic Encephalopathy in a Large Multi-Center Cohort Gastroenterology 2019, 156: s-562. DOI: 10.1016/s0016-5085(19)38297-6.
• 246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic HepatitisLang S, Duan Y, Liu J, Ventura-Cots M, Lucey M, Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Ho S, Bataller R, Tu X, Stärkel P, Fouts D, Schnabl B. 246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis Gastroenterology 2019, 156: s-1186. DOI: 10.1016/s0016-5085(19)39939-1.
• 573 – Predictive Factors for the Development of Acute-Onchronic Liver Failure in a North American Cohort of Hospitalized Cirrhotic Patients with DecompensationWong F, Reddy K, Tandon P, O'Leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. 573 – Predictive Factors for the Development of Acute-Onchronic Liver Failure in a North American Cohort of Hospitalized Cirrhotic Patients with Decompensation Gastroenterology 2019, 156: s-1205. DOI: 10.1016/s0016-5085(19)39995-0.
• Sa1570 – Underutilization of Hospice in Inpatients with Cirrhosis: the Nacseld ExperienceO'Leary J, Tandon P, Reddy K, Biggins S, Wong F, Kamath P, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas H, Thuluvath P, Subramanian R, Thacker L, Bajaj J. Sa1570 – Underutilization of Hospice in Inpatients with Cirrhosis: the Nacseld Experience Gastroenterology 2019, 156: s-1238. DOI: 10.1016/s0016-5085(19)40093-0.
• Tu1519 – The Natural Histyory of Stages 2 & 3 Acute Kidney Injury (AKI) in Patients with Decompensated Cirrhosis and AscitesWong F, Reddy K, Tandon P, O'Leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. Tu1519 – The Natural Histyory of Stages 2 & 3 Acute Kidney Injury (AKI) in Patients with Decompensated Cirrhosis and Ascites Gastroenterology 2019, 156: s-1351. DOI: 10.1016/s0016-5085(19)40399-5.
• Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohortBajaj JS, O’Leary J, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia‐Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohort Alimentary Pharmacology & Therapeutics 2019, 49: 1518-1527. PMID: 31032966, PMCID: PMC6538445, DOI: 10.1111/apt.15265.
• Impact of Chronic Kidney Disease on Outcomes in CirrhosisWong F, Reddy K, O’Leary J, Tandon P, Biggins SW, Garcia‐Tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis Liver Transplantation 2019, 25: 870-880. PMID: 30908855, DOI: 10.1002/lt.25454.
• SAT-093-Underutilization of hospice in inpatients with cirrhosis: The NACSELD experienceO’leary J, Reddy R, Tandon P, Biggins S, Wong F, Garcia-Tsao G, Kamath P, Maliakkal B, Lai J, Fallon M, Thuluvath P, Subramanian R, Vargas H, Thacker L, Bajaj J. SAT-093-Underutilization of hospice in inpatients with cirrhosis: The NACSELD experience Journal Of Hepatology 2019, 70: e669. DOI: 10.1016/s0618-8278(19)31333-7.
• SAT-013-Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohortBajaj J, Tandon P, O’leary J, Wong F, Garcia-Tsao G, Biggins S, Kamath P, Thuluvath P, Lai J, Vargas H, Subramanian R, Maliakkal B, Fallon M, Thacker L, Reddy R. SAT-013-Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort Journal Of Hepatology 2019, 70: e630-e631. DOI: 10.1016/s0618-8278(19)31256-3.
• SAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascitesWong F, Reddy R, Tandon P, O’leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. SAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites Journal Of Hepatology 2019, 70: e692. DOI: 10.1016/s0618-8278(19)31379-9.
• SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensationWong F, Reddy R, Tandon P, O’leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation Journal Of Hepatology 2019, 70: e691-e692. DOI: 10.1016/s0618-8278(19)31378-7.
• LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertensionGarcia-Tsao G, Bosch J, Kayali Z, Harrison S, Abdelmalek M, Lawitz E, Satapathy S, Ghabril M, Shiffman M, Younes Z, Thuluvath P, Berzigotti A, Albillos A, Robinson J, Chan J, Hagerty D, Sanyal A. LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension Journal Of Hepatology 2019, 70: e127. DOI: 10.1016/s0618-8278(19)30225-7.
• Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease ExperienceO’Leary J, Bajaj JS, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia‐Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Reddy K. Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience Liver Transplantation 2019, 25: 571-579. PMID: 30724010, DOI: 10.1002/lt.25426.
• Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal HypertensionAbraldes JG, Trebicka J, Chalasani N, D’Amico G, Rockey DC, Shah VH, Bosch J, Garcia‐Tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension Hepatology 2019, 69: 1287-1299. PMID: 30318607, DOI: 10.1002/hep.30314.
• Esophageal VaricesJakab S, Garcia-Tsao G. Esophageal Varices 2018, 195-208. DOI: 10.1007/978-3-319-98506-0_15.
• Acute‐on‐Chronic Liver Failure: An Old Entity in Search of ClarityGarcia‐Tsao G. Acute‐on‐Chronic Liver Failure: An Old Entity in Search of Clarity Hepatology Communications 2018, 2: 1421-1424. PMID: 30556031, PMCID: PMC6287486, DOI: 10.1002/hep4.1287.
• Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal HypertensionGarcia‐Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos‐Orozco J, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension Hepatology 2018, 69: 717-728. PMID: 30063802, PMCID: PMC6587783, DOI: 10.1002/hep.30199.
• Reply:O’Leary J, Reddy K, Wong F, Garcia‐Tsao G, Kamath PS, Thacker LR, Bajaj JS. Reply: Hepatology 2018, 68: 2046-2048. PMID: 30199577, DOI: 10.1002/hep.30264.
• PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive AnticoagulationTo UK, Garcia‐Tsao G. PRO: Patients With Advanced Cirrhosis and Portal Vein Thrombosis Should Receive Anticoagulation Clinical Liver Disease 2018, 12: 74-79. PMID: 30988915, PMCID: PMC6385918, DOI: 10.1002/cld.717.
• Author response to Letter to the Editor “Post‐paracentesis hemoperitoneum ‐ time to become more careful!”Hung A, Garcia‐Tsao G. Author response to Letter to the Editor “Post‐paracentesis hemoperitoneum ‐ time to become more careful!” Liver International 2018, 38: 1698-1699. PMID: 30145847, DOI: 10.1111/liv.13740.
• ReplyO’Leary J, Reddy K, Wong F, Garcia‐Tsao G, Kamath PS, Bajaj JS. Reply Hepatology 2018, 68: 791-791. PMID: 29663463, DOI: 10.1002/hep.30032.
• AscitesGarcia‐Tsao G. Ascites 2018, 127-150. DOI: 10.1002/9781119237662.ch9.
• Tu1542 - Platelet Count Increases after Viral Suppression in Chronic HCV, Independent of Fibrosis StageSayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia-Tsao G. Tu1542 - Platelet Count Increases after Viral Suppression in Chronic HCV, Independent of Fibrosis Stage Gastroenterology 2018, 154: s-1245-s-1246. DOI: 10.1016/s0016-5085(18)34092-7.
• Tu1543 - Usefulness of Repeat Liver Stiffness Measurements (LSM) by Transient Elastography (TE) and LSM by Acoustic Radiation Force Impulse (ARFI) in the Clinical Evaluation of Cirrhosis in Patients in whom Initial TE is EquivocalSayyar M, de Oliveira A, Jangouk P, Bernardo A, Garcia-Tsao G. Tu1543 - Usefulness of Repeat Liver Stiffness Measurements (LSM) by Transient Elastography (TE) and LSM by Acoustic Radiation Force Impulse (ARFI) in the Clinical Evaluation of Cirrhosis in Patients in whom Initial TE is Equivocal Gastroenterology 2018, 154: s-1246. DOI: 10.1016/s0016-5085(18)34093-9.
• 499 - Primary SBP Prophylaxis is Associated with Higher ICU Admission and 30-Day Mortality Compared to Secondary SBP ProphylaxisBajaj J, O'Leary J, Tandon P, Kamath P, Wong F, Garcia-Tsao G, Lai J, Thuluvath P, Subramanian R, Vargas H, Fallon M, Thacker L, Reddy K. 499 - Primary SBP Prophylaxis is Associated with Higher ICU Admission and 30-Day Mortality Compared to Secondary SBP Prophylaxis Gastroenterology 2018, 154: s-1091. DOI: 10.1016/s0016-5085(18)33633-3.
• NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosisO'Leary JG, Reddy KR, Garcia‐Tsao G, Biggins SW, Wong F, Fallon MB, Subramanian RM, Kamath PS, Thuluvath P, Vargas HE, Maliakkal B, Tandon P, Lai J, Thacker LR, Bajaj JS. NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis Hepatology 2018, 67: 2367-2374. PMID: 29315693, DOI: 10.1002/hep.29773.
• GS-015 Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxisBajaj J, Tandon P, O’leary J, Wong F, Biggins S, Garcia-Tsao G, Kamath P, Maliakkal B, Fallon M, Thuluvath P, Lai J, Subramanian R, Vargas H, Thacker L, Reddy R. GS-015 Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis Journal Of Hepatology 2018, 68: s66. DOI: 10.1016/s0168-8278(18)30353-2.
• LBP-019 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASHBosch J, Bureau C, Chalasani N, Lawitz E, Abdelmalek M, Rinella M, Harrison S, Berzigotti A, Sanyal A, Noureddin M, Rockey D, Ber T, Ilan Y, Garcia-Tsao G. LBP-019 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH Journal Of Hepatology 2018, 68: s115. DOI: 10.1016/s0168-8278(18)30446-x.
• LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertensionChalasani N, Garcia-Tsao G, Goodman Z, Lawitz E, Abdelmalek M, Rinella M, Ryan M, Noureddin M, Jue C, Pyko M, Allgood A, Shlevin H, Horton R, Zomer E, Traber P, Loomba R, Tetri B, Sanyal A, Harrison S. LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension Journal Of Hepatology 2018, 68: s100-s101. DOI: 10.1016/s0168-8278(18)30420-3.
• Regression of HCV cirrhosis: Time will tellGarcia‐Tsao G. Regression of HCV cirrhosis: Time will tell Hepatology 2018, 67: 1651-1653. PMID: 29222930, PMCID: PMC6016365, DOI: 10.1002/hep.29720.
• Cirrhosis and Portal Hypertension: Staging and PrognosisGarcia-Tsao G. Cirrhosis and Portal Hypertension: Staging and Prognosis 2018, 1-13. DOI: 10.1007/978-3-319-72628-1_1.
• THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIABrandt E, Haghighat L, Garcia-Tsao G, Henderson K, Pollak J, Proctor D, Young L. THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA Journal Of The American College Of Cardiology 2018, 71: a2393. DOI: 10.1016/s0735-1097(18)32934-6.
• Acute kidney injury, but not sepsis, is associated with higher procedure‐related bleeding in patients with decompensated cirrhosisHung A, Garcia‐Tsao G. Acute kidney injury, but not sepsis, is associated with higher procedure‐related bleeding in patients with decompensated cirrhosis Liver International 2018, 38: 1437-1441. PMID: 29393567, PMCID: PMC6072624, DOI: 10.1111/liv.13712.
• Patient Perspectives on Adherence to the New Hepatitis C Antiviral Medications: ‘A New Lease on Life’Giordano N, Brinn A, Garcia-Tsao G, Martino S. Patient Perspectives on Adherence to the New Hepatitis C Antiviral Medications: ‘A New Lease on Life’ The Qualitative Report 2018 DOI: 10.46743/2160-3715/2018.2740.
• 15 Ascites and HyponatremiaGarcia-Tsao G. 15 Ascites and Hyponatremia 2018, 220-232.e4. DOI: 10.1016/b978-0-323-37591-7.00015-x.
• Management of Portal HypertensionGarcia‐Tsao G, Abraldes J. Management of Portal Hypertension 2017, 304-335. DOI: 10.1002/9781119251316.ch12.
• Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiationBhutta A, Garcia‐Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation Alimentary Pharmacology & Therapeutics 2017, 47: 78-85. PMID: 28994122, PMCID: PMC6016372, DOI: 10.1111/apt.14366.
• Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysisAlbillos A, Zamora J, Martínez J, Arroyo D, Ahmad I, De‐la‐Peña J, Garcia‐Pagán J, Lo G, Sarin S, Sharma B, Abraldes JG, Bosch J, Garcia‐Tsao G. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis Hepatology 2017, 66: 1219-1231. PMID: 28543862, PMCID: PMC5605404, DOI: 10.1002/hep.29267.
• Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient OutcomesWong F, O'Leary J, Reddy K, Garcia-Tsao G, Fallon M, Biggins S, Subramanian R, Thuluvath P, Kamath P, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj J. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes The American Journal Of Gastroenterology 2017, 112: 1103. PMID: 28440305, DOI: 10.1038/ajg.2017.122.
• Reply to Risk Stratification in Acute Variceal BleedingFortune B, Ciarleglio M, Deng Y, Garcia-Tsao G. Reply to Risk Stratification in Acute Variceal Bleeding Journal Of Clinical Gastroenterology 2017, 1. DOI: 10.1097/00004836-900000000-98090.
• 421 Nacseld Acute-on-Chronic Liver Failure (NACSELD-ACLF) Predicts 30-Day Mortality in Admitted Cirrhotic PatientsO'Leary J, Reddy K, Tandon P, Kamath P, Wong F, Garcia-Tsao G, Lai J, Biggins S, Fallon M, Subramanian R, Thuluvath P, Maliakkal B, Thacker L, Bajaj J. 421 Nacseld Acute-on-Chronic Liver Failure (NACSELD-ACLF) Predicts 30-Day Mortality in Admitted Cirrhotic Patients Gastroenterology 2017, 152: s1056-s1057. DOI: 10.1016/s0016-5085(17)33569-2.
• Tu1549 Albumin Use and Acute Kidney Injury in a Large Real-World Analysis of Cirrhotic InpatientsBajaj J, O'Leary J, Wong F, Garcia-Tsao G, Tandon P, Biggins S, Kamath P, Lai J, Subramanian R, Fallon M, Maliakkal B, Vargas H, Thuluvath P, Thacker L, Reddy K. Tu1549 Albumin Use and Acute Kidney Injury in a Large Real-World Analysis of Cirrhotic Inpatients Gastroenterology 2017, 152: s906. DOI: 10.1016/s0016-5085(17)33097-4.
• Primary and secondary prophylaxis of esophageal variceal bleedingJangouk P, Garcia-Tsao G. Primary and secondary prophylaxis of esophageal variceal bleeding Techniques And Innovations In Gastrointestinal Endoscopy 2017, 19: 84-89. DOI: 10.1016/j.tgie.2017.03.004.
• Validating, deconstructing and refining Baveno criteria for ruling out high‐risk varices in patients with compensated cirrhosisJangouk P, Turco L, De Oliveira A, Schepis F, Villa E, Garcia‐Tsao G. Validating, deconstructing and refining Baveno criteria for ruling out high‐risk varices in patients with compensated cirrhosis Liver International 2017, 37: 1177-1183. PMID: 28160373, PMCID: PMC5511584, DOI: 10.1111/liv.13379.
• Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and ManagementShung DL, Garcia‐Tsao G. Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and Management Hepatology 2017, 65: 1038-1038. PMID: 28032650, DOI: 10.1002/hep.29026.
• THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammationWinters A, Luedtke S, Moreland A, Jangouk P, Weng G, Silveira M, Davitkov P, Duarte-Rojo A, Cheung R, Garcia-Tsao G, Falck-Ytter Y, Branch A, Bräu N. THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation Journal Of Hepatology 2017, 66: s280. DOI: 10.1016/s0168-8278(17)30876-0.
• LBP-523 A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysisTurco L, Villanueva C, La Mura V, Garcia-Pagan J, Reiberger T, Genesca J, Groszmann R, Sharma B, Merkel C, Bureau C, Alvarado E, Abraldes J, Albillos A, Banares R, Peck-Radosavljevic M, Augustin S, Sarin S, Bosch J, Garcia-Tsao G. LBP-523 A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis Journal Of Hepatology 2017, 66: s103-s104. DOI: 10.1016/s0168-8278(17)30468-3.
• LBP-516 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosisIlan Y, Harrison S, Traber P, Chalasani N, Garcia-Tsao G. LBP-516 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis Journal Of Hepatology 2017, 66: s100. DOI: 10.1016/s0168-8278(17)30461-0.
• FRI-025 Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatientsBajaj J, O’leary J, Wong F, Garcia-Tsao G, Tandon P, Biggins S, Kamath P, Lai J, Fallon M, Subramanian R, Maliakkal B, Thuluvath P, Vargas H, Thacker L, Reddy R, Disease N. FRI-025 Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients Journal Of Hepatology 2017, 66: s378. DOI: 10.1016/s0168-8278(17)31103-0.
• Chapter 36 AscitesGarcia-Tsao G. Chapter 36 Ascites 2017, 475-484. DOI: 10.1016/b978-0-12-804274-8.00036-9.
• Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseasesGarcia‐Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases Hepatology 2016, 65: 310-335. PMID: 27786365, DOI: 10.1002/hep.28906.
• A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosisTandon P, Reddy KR, O'Leary JG, Garcia‐Tsao G, Abraldes JG, Wong F, Biggins SW, Maliakkal B, Fallon MB, Subramanian RM, Thuluvath P, Kamath PS, Thacker LR, Bajaj JS, Disease N. A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosis Hepatology 2016, 65: 217-224. PMID: 27775842, DOI: 10.1002/hep.28900.
• ¿Qué es la hipertensión portal no cirrótica idiopática?García‐Tsao G. ¿Qué es la hipertensión portal no cirrótica idiopática? Clinical Liver Disease 2016, 8: s39-s42. PMID: 31041095, PMCID: PMC6490228, DOI: 10.1002/cld.600.
• Corrigendum to “Management of the critically ill patients with cirrhosis: A multidisciplinary perspective”Nadim MK, Durand F, Kellum JA, Levitsky J, O’Leary J, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS. Corrigendum to “Management of the critically ill patients with cirrhosis: A multidisciplinary perspective” Journal Of Hepatology 2016, 65: 452. PMID: 27241199, DOI: 10.1016/j.jhep.2016.05.001.
• Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker mattersNjei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters Gut 2016, 65: 1393. PMID: 27207973, DOI: 10.1136/gutjnl-2016-312129.
• Su1493 Non-Response to Empirical Treatment for Spontaneous Bacterial Peritonitis (SBP): Incidence, Risk Factors, Clinical Impact, and Antibiotic ChoicesTo U, Delisle A, Garcia-Tsao G. Su1493 Non-Response to Empirical Treatment for Spontaneous Bacterial Peritonitis (SBP): Incidence, Risk Factors, Clinical Impact, and Antibiotic Choices Gastroenterology 2016, 150: s1109-s1110. DOI: 10.1016/s0016-5085(16)33749-0.
• Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved SurvivalBhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival Gastroenterology 2016, 150: s1084-s1085. DOI: 10.1016/s0016-5085(16)33659-9.
• Su1513 In-Hospital Mortality Related to Hepatic Encephalopathy Is Independent of ACLF and Varies Significantly Across North America: NACSELD ExperienceBajaj J, Reddy K, Tandon P, Garcia-Tsao G, Wong F, Kamath P, Biggins S, Fallon M, Maliakkal B, Thuluvath P, Subramanian R, Vargas H, Lai J, Thacker L, O'Leary J. Su1513 In-Hospital Mortality Related to Hepatic Encephalopathy Is Independent of ACLF and Varies Significantly Across North America: NACSELD Experience Gastroenterology 2016, 150: s1117. DOI: 10.1016/s0016-5085(16)33769-6.
• Tu1649 Predicting Mortality After Discharge From Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky ScoreTandon P, Reddy K, O'Leary J, Garcia-Tsao G, Wong F, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. Tu1649 Predicting Mortality After Discharge From Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score Gastroenterology 2016, 150: s1156. DOI: 10.1016/s0016-5085(16)33906-3.
• The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosisBajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia‐Tsao G, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas H, Thacker LR, O'Leary JG, Disease N. The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis Hepatology 2016, 64: 200-208. PMID: 26690389, PMCID: PMC4700508, DOI: 10.1002/hep.28414.
• Approach to the Patient with Ascites and Its ComplicationsGarcia‐Tsao G. Approach to the Patient with Ascites and Its Complications 2016, 447-458. DOI: 10.1002/9781118512104.ch55.
• THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved SurvivalBhutta A, Garcia-Tsao G, Reddy R, Tandon P, Wong F, O’Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival Journal Of Hepatology 2016, 64: s245. DOI: 10.1016/s0168-8278(16)00253-1.
• THU-373 Predicting Mortality after Discharge from Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky ScoreTandon P, Reddy R, O’Leary J, Garcia-Tsao G, Wong F, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. THU-373 Predicting Mortality after Discharge from Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score Journal Of Hepatology 2016, 64: s282. DOI: 10.1016/s0168-8278(16)00340-8.
• Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of CirrhosisRipoll C, Augustin S, Reiberger T, Moreau R, Salerno F, Albillos A, Abraldes J, Garcia-Tsao G. Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis 2016, 333-339. DOI: 10.1007/978-3-319-23018-4_33.
• Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal BleedingAugustin S, Albillos A, Ripoll C, Abraldes J, Salerno F, Moreau R, Reiberger T, Garcia-Tsao G. Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding 2016, 341-353. DOI: 10.1007/978-3-319-23018-4_34.
• Introduction and Survey ResultsGarcia-Tsao G, Ripoll C, Augustin S, Reiberger T, Albillos A, Moreau R, Salerno F, Abraldes J. Introduction and Survey Results 2016, 303-309. DOI: 10.1007/978-3-319-23018-4_30.
• Consensus Statements: Preventing Recurrent Variceal Hemorrhage and Other Decompensating EventsAbraldes J, Albillos A, Augustin S, Moreau R, Reiberger T, Ripoll C, Salerno F, Garcia-Tsao G. Consensus Statements: Preventing Recurrent Variceal Hemorrhage and Other Decompensating Events 2016, 365-367. DOI: 10.1007/978-3-319-23018-4_36.
• Secondary Prophylaxis in Special Patient PopulationsReiberger T, Moreau R, Ripoll C, Albillos A, Augustin S, Salerno F, Abraldes J, Garcia-Tsao G. Secondary Prophylaxis in Special Patient Populations 2016, 317-332. DOI: 10.1007/978-3-319-23018-4_32.
• Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing CareAlbillos A, Abraldes J, Ripoll C, Reiberger T, Augustin S, Salerno F, Moreau R, Garcia-Tsao G. Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care 2016, 311-316. DOI: 10.1007/978-3-319-23018-4_31.
• THU-347 Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated CirrhosisTurco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Rossi R, Villa E, Schepis F. THU-347 Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated Cirrhosis Journal Of Hepatology 2016, 64: s270-s271. DOI: 10.1016/s0168-8278(16)00314-7.
• Issues in Trial Design and Areas Needing Further ResearchAbraldes J, Salerno F, Augustin S, Ripoll C, Reiberger T, Moreau R, Albillos A, Garcia-Tsao G. Issues in Trial Design and Areas Needing Further Research 2016, 355-363. DOI: 10.1007/978-3-319-23018-4_35.
• Ascites and Its ComplicationsGarcia‐Tsao G. Ascites and Its Complications 2015, 2087-2106. DOI: 10.1002/9781118512074.ch106.
• Corrigendum to “Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites” [J Hepatol 2015;62:968–974]Angeli P, Ginès P, Wong F, Bernardi M, Boyer T, Gerbes A, Moreau R, Jalan R, Sarin S, Piano S, Moore K, Lee S, Durand F, Salerno F, Caraceni P, Kim W, Arroyo V, Garcia-Tsao G. Corrigendum to “Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites” [J Hepatol 2015;62:968–974] Journal Of Hepatology 2015, 63: 290. DOI: 10.1016/j.jhep.2015.04.001.
• High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver diseaseReddy KR, O'Leary JG, Kamath PS, Fallon MB, Biggins SW, Wong F, Patton HM, Garcia‐Tsao G, Subramanian RM, Thacker LR, Bajaj JS, Disease F. High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver disease Liver Transplantation 2015, 21: 881-888. PMID: 25845966, DOI: 10.1002/lt.24139.
• Natural History of CirrhosisGarcia-Tsao G. Natural History of Cirrhosis 2015, 13-20. DOI: 10.1007/978-3-319-13614-1_2.
• P0120 : The 3-month readmission rate remains unacceptably high in a large multi-center cohort of cirrhotic patientsBajaj J, Reddy K, Garcia-Tsao G, Wong F, Fallon M, Subramanian R, Biggins S, Maliakkal B, Kamath P, Thuluvath P, Thacker L, O’leary J, behalf of NACSELD. O. P0120 : The 3-month readmission rate remains unacceptably high in a large multi-center cohort of cirrhotic patients Journal Of Hepatology 2015, 62: s345-s346. DOI: 10.1016/s0168-8278(15)30340-8.
• Mo1892 Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient OutcomesWong F, O'Leary J, Reddy K, Garcia-Tsao G, Fallon M, Biggins S, Subramanian R, Thuluvath P, Kamath P, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj J. Mo1892 Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes Gastroenterology 2015, 148: s-1075. DOI: 10.1016/s0016-5085(15)33674-x.
• 575 The 3-Month Readmission Rate Remains Unacceptably High in a Large Multi-Center Cohort of Cirrhotic PatientsBajaj J, Reddy K, Garcia-Tsao G, Wong F, Fallon M, Subramanian R, Biggins S, Maliakkal B, Kamath P, Thuluvath P, Thacker L, O'Leary J. 575 The 3-Month Readmission Rate Remains Unacceptably High in a Large Multi-Center Cohort of Cirrhotic Patients Gastroenterology 2015, 148: s-982-s-983. DOI: 10.1016/s0016-5085(15)33360-6.
• P0119 : Validation Of The NACSELD Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) score in an independent multicenter cohortO’Leary J, Reddy K, Garcia-Tsao G, Biggins S, Wong F, Fallon M, Subramanian R, Kamath P, Thuluvath P, Maliakkal B, Patton H, Tandon P, Thacker L, Bajaj J, behalf of NACSESLD. O. P0119 : Validation Of The NACSELD Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) score in an independent multicenter cohort Journal Of Hepatology 2015, 62: s345. DOI: 10.1016/s0168-8278(15)30339-1.
• 591 Validation of Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) Definition for 30-Day Mortality Prediction in Infected and Uninfected Hospitalized Cirrhotic PatientsO'Leary J, Reddy K, Garcia-Tsao G, Biggins S, Wong F, Fallon M, Subramanian R, Kamath P, Thuluvath P, Maliakkal B, Patton H, Tandon P, Thacker L, Bajaj J. 591 Validation of Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) Definition for 30-Day Mortality Prediction in Infected and Uninfected Hospitalized Cirrhotic Patients Gastroenterology 2015, 148: s-988. DOI: 10.1016/s0016-5085(15)33376-x.
• O072 : Statin use significantly decreases decompensation and death in veterans with hepatitis C-related compensated cirrhosisMohanty A, Tate J, Garcia-Tsao G. O072 : Statin use significantly decreases decompensation and death in veterans with hepatitis C-related compensated cirrhosis Journal Of Hepatology 2015, 62: s226-s227. DOI: 10.1016/s0168-8278(15)30086-6.
• P0199 : Acute kidney injury in cirrhosis: Baseline serum creatinine predicts patient outcomesWong F, O’Leary J, Reddy K, Garcia-Tsao G, Fallon M, Biggins S, Subramanian R, Thuluvath P, Kamath P, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj J, Disease N. P0199 : Acute kidney injury in cirrhosis: Baseline serum creatinine predicts patient outcomes Journal Of Hepatology 2015, 62: s380. DOI: 10.1016/s0168-8278(15)30418-9.
• Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injuryBelcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen‐Philbrook H, Ansari N, Coca SG, Garcia‐Tsao G, Parikh CR. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury Hepatology 2014, 60: 622-632. PMID: 24375576, PMCID: PMC4065642, DOI: 10.1002/hep.26980.
• Survival in infection‐related acute‐on‐chronic liver failure is defined by extrahepatic organ failuresBajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, Fallon MB, Garcia‐Tsao G, Maliakkal B, Malik R, Subramanian RM, Thacker LR, Kamath PS, Disease T. Survival in infection‐related acute‐on‐chronic liver failure is defined by extrahepatic organ failures Hepatology 2014, 60: 250-256. PMID: 24677131, PMCID: PMC4077926, DOI: 10.1002/hep.27077.
• Prognostic Factors in Compensated and Decompensated CirrhosisRipoll C, Zipprich A, Garcia-Tsao G. Prognostic Factors in Compensated and Decompensated Cirrhosis Current Hepatology Reports 2014, 13: 171-179. DOI: 10.1007/s11901-014-0234-6.
• Sa1004 Measurement of Liver and Spleen Stiffness by ARFI Elastography: Intra-and Inter-Observer Variability and Predictors of VariabilityBalakrishnan M, Souza F, Munoz C, Augustin S, Loo N, Deng Y, Ciarleglio M, Garcia-Tsao G. Sa1004 Measurement of Liver and Spleen Stiffness by ARFI Elastography: Intra-and Inter-Observer Variability and Predictors of Variability Gastroenterology 2014, 146: s-934. DOI: 10.1016/s0016-5085(14)63395-3.
• Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic FactorsSanchez M, Augustin S, Balakrishnan M, Re V, Tate J, Garcia-Tsao G. Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic Factors Gastroenterology 2014, 146: s-974-s-975. DOI: 10.1016/s0016-5085(14)63541-1.
• Mo1027 Differences in Creatinine Between Genders Could Disadvantage Infected Cirrhotic Women: The Nacseld ExperienceO'Leary J, Wong F, Kamath P, Reddy K, Patton H, Biggins S, Fallon M, Garcia-Tsao G, Subramanian R, Maliakkal B, Malik R, Thacker L, Bajaj J. Mo1027 Differences in Creatinine Between Genders Could Disadvantage Infected Cirrhotic Women: The Nacseld Experience Gastroenterology 2014, 146: s-989. DOI: 10.1016/s0016-5085(14)63596-4.
• P1013 MEASUREMENT OF LIVER AND SPLEEN STIFFNESS BY ARFI ELASTOGRAPHY: INTRA- AND INTER-OBSERVER VARIABILITY AND PREDICTORS OF VARIABILITYBalakrishnan M, Souza F, Munoz C, Augustin S, Loo N, Deng Y, Ciarleglio M, Garcia-Tsao G. P1013 MEASUREMENT OF LIVER AND SPLEEN STIFFNESS BY ARFI ELASTOGRAPHY: INTRA- AND INTER-OBSERVER VARIABILITY AND PREDICTORS OF VARIABILITY Journal Of Hepatology 2014, 60: s412-s413. DOI: 10.1016/s0168-8278(14)61173-9.
• P502 SPONTANEOUS BACTERIAL PERITONITIS AND BACTEREMIA PREDICT MORTALITY IN CIRRHOSIS DESPITE PROPHYLACTIC MEASURES: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELDBiggins S, O'Leary J, Reddy K, Wong F, Kamath P, Patton H, Fallon M, Garcia-Tsao G, Subramanian R, Thuluvath P, Maliakkal B, Koch D, Malik R, Thacker L, Bajaj J. P502 SPONTANEOUS BACTERIAL PERITONITIS AND BACTEREMIA PREDICT MORTALITY IN CIRRHOSIS DESPITE PROPHYLACTIC MEASURES: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELD Journal Of Hepatology 2014, 60: s237. DOI: 10.1016/s0168-8278(14)60664-4.
• P943 DIFFERENCES IN CREATININE BETWEEN GENDERS COULD DISADVANTAGE INFECTED CIRRHOTIC WOMEN: THE NACSELD EXPERIENCEBajaj J, O'Leary J, Reddy K, Wong F, Fallon M, Biggins S, Patton H, Maliakkal B, Thuluvath P, Garcia-Tsao G, Koch D, Thacker L, Kamath P. P943 DIFFERENCES IN CREATININE BETWEEN GENDERS COULD DISADVANTAGE INFECTED CIRRHOTIC WOMEN: THE NACSELD EXPERIENCE Journal Of Hepatology 2014, 60: s389-s390. DOI: 10.1016/s0168-8278(14)61104-1.
• Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patientsBuck M, Garcia‐Tsao G, Groszmann RJ, Stalling C, Grace ND, Burroughs AK, Patch D, Matloff DS, Clopton P, Chojkier M. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients Hepatology 2014, 59: 1052-1059. PMID: 24115225, DOI: 10.1002/hep.26755.
• Serum B‐type natriuretic peptide in the initial workup of patients with new onset ascites: A diagnostic accuracy studyFarias AQ, Silvestre OM, Garcia‐Tsao G, Seguro L, Mazo D, Bacal F, Andrade JL, Gonçalves LL, Strunz C, Ramos DS, Polli D, Pugliese V, Rodrigues AC, Furtado MS, Carrilho FJ, D'Albuquerque LA. Serum B‐type natriuretic peptide in the initial workup of patients with new onset ascites: A diagnostic accuracy study Hepatology 2014, 59: 1043-1051. PMID: 23907731, DOI: 10.1002/hep.26643.
• New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and InfectionWong F, O'Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia–Tsao G, Subramanian RM, Malik R, Maliakkal B, Thacker LR, Bajaj JS, Disease N. New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection Gastroenterology 2013, 145: 1280-1288.e1. PMID: 23999172, PMCID: PMC4418483, DOI: 10.1053/j.gastro.2013.08.051.
• Serum B-type natriuretic peptide is more accurate than ascites analyses in the diagnosis of ascites related to heart failureFarias A, Silvestre O, Bacal F, Garcia-Tsao G, Seguro L, Mazo D, Andrade J, Furtado M, Carrilho F, D'Albuquerque L. Serum B-type natriuretic peptide is more accurate than ascites analyses in the diagnosis of ascites related to heart failure European Heart Journal 2013, 34: p4241-p4241. DOI: 10.1093/eurheartj/eht309.p4241.
• Hypervolemic hyponatremia: Clinical significance and managementFortune BE, Garcia‐Tsao G. Hypervolemic hyponatremia: Clinical significance and management Clinical Liver Disease 2013, 2: 109-112. PMID: 30992838, PMCID: PMC6448632, DOI: 10.1002/cld.179.
• Bevacizumab: Finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasiaYoung LH, Henderson KJ, White RI, Garcia‐Tsao G. Bevacizumab: Finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia Hepatology 2013, 58: 442-445. PMID: 23686865, DOI: 10.1002/hep.26472.
• Tu2048 Histological Features Using Quantitative Morphometric Digital Image Analysis Can Predict Hpvg and Help in Sub-Classification of CirrhosisAlduaij A, Jain D, Lesniak A, Demetris A, Garcia-Tsao G, Scott R. Tu2048 Histological Features Using Quantitative Morphometric Digital Image Analysis Can Predict Hpvg and Help in Sub-Classification of Cirrhosis Gastroenterology 2013, 144: s-912. DOI: 10.1016/s0016-5085(13)63404-6.
• Acute Kidney Injury in Patients With Cirrhosis: Perils and PromiseBelcher JM, Parikh CR, Garcia–Tsao G. Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise Clinical Gastroenterology And Hepatology 2013, 11: 1550-1558. PMID: 23583467, PMCID: PMC3840046, DOI: 10.1016/j.cgh.2013.03.018.
• Association of AKI With mortality and complications in hospitalized patients with cirrhosisBelcher JM, Garcia‐Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR. Association of AKI With mortality and complications in hospitalized patients with cirrhosis Hepatology 2012, 57: 753-762. PMID: 22454364, PMCID: PMC3390443, DOI: 10.1002/hep.25735.
• When the Spleen Gets Tough, the Varices Get GoingCastéra L, García–Tsao G. When the Spleen Gets Tough, the Varices Get Going Gastroenterology 2012, 144: 19-22. PMID: 23164570, DOI: 10.1053/j.gastro.2012.11.015.
• High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver CenterTandon P, DeLisle A, Topal JE, Garcia–Tsao G. High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver Center Clinical Gastroenterology And Hepatology 2012, 10: 1291-1298. PMID: 22902776, PMCID: PMC3891826, DOI: 10.1016/j.cgh.2012.08.017.
• The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume ParacentesisBari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia–Tsao G. The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis Clinical Gastroenterology And Hepatology 2012, 10: 1169-1175. PMID: 22801062, PMCID: PMC3678262, DOI: 10.1016/j.cgh.2012.06.027.
• Prognostic indicators of survival in patients with compensated and decompensated cirrhosisZipprich A, Garcia‐Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis Liver International 2012, 32: 1407-1414. PMID: 22679906, PMCID: PMC3713489, DOI: 10.1111/j.1478-3231.2012.02830.x.
• Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education ClassBari K, Augustin S, Eggers C, Hashem H, Desai M, Shea M, Wongcharatrawee S, Lim J, Garcia-Tsao G. Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education Class Gastroenterology 2012, 142: s-967. DOI: 10.1016/s0016-5085(12)63744-5.
• Spontaneous bacterial peritonitisGarcia‐Tsao G. Spontaneous bacterial peritonitis 2012, 745-750. DOI: 10.1002/9781118321386.ch100.
• ParacentesisDe Gottardi A, Yeo C, Garcia‐Tsao G. Paracentesis 2012, 1158-1162. DOI: 10.1002/9781118321386.ch154.
• Functional Gastrointestinal DiseaseHawkey C, Bosch J, Richter J, Garcia‐Tsao G, Chan F. Functional Gastrointestinal Disease 2012, 54-60. DOI: 10.1002/9781118321386.ch10.
• AscitesGarcia‐Tsao G. Ascites 2012, 103-106. DOI: 10.1002/9781118321386.ch17.
• Quantitative histological‐hemodynamic correlations in cirrhosisSethasine S, Jain D, Groszmann RJ, Garcia‐Tsao G. Quantitative histological‐hemodynamic correlations in cirrhosis Hepatology 2012, 55: 1146-1153. PMID: 22109744, PMCID: PMC3721182, DOI: 10.1002/hep.24805.
• In Memoriam: Harold O. Conn, M.D.Boyer J, Garcia‐Tsao G, Groszmann R. In Memoriam: Harold O. Conn, M.D. Hepatology 2012, 55: 658-658. DOI: 10.1002/hep.25550.
• The presence of esophageal varices (EV), but not treatment with beta-blockers, is associated with a poorer survival in patients with cirrhosis and ascitesZipprich A, Garcia-Tsao G, Seufferlein T, Dollinger M. The presence of esophageal varices (EV), but not treatment with beta-blockers, is associated with a poorer survival in patients with cirrhosis and ascites Zeitschrift Für Gastroenterologie 2012, 50 DOI: 10.1055/s-0031-1295840.
• Chapter 18 AscitesGarcia-Tsao G. Chapter 18 Ascites 2012, 283-295. DOI: 10.1016/b978-1-4377-0881-3.00018-8.
• 156 Cirrhosis and Its SequelaeGarcia-Tsao G. 156 Cirrhosis and Its Sequelae 2012, 999-1007. DOI: 10.1016/b978-1-4377-1604-7.00156-1.
• Intensive care of the patient with cirrhosisOlson JC, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia‐Tsao G, Kamath PS. Intensive care of the patient with cirrhosis Hepatology 2011, 54: 1864-1872. PMID: 21898477, DOI: 10.1002/hep.24622.
• Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*Boyer TD, Sanyal AJ, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1* Liver Transplantation 2011, 17: 1328-1332. PMID: 21837734, PMCID: PMC3760727, DOI: 10.1002/lt.22395.
• Obesity is an independent risk factor for clinical decompensation in patients with cirrhosisBerzigotti A, Garcia‐Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia‐Pagan J, Patch D, Matloff DS, Groszmann RJ. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis Hepatology 2011, 54: 555-561. PMID: 21567436, PMCID: PMC3144991, DOI: 10.1002/hep.24418.
• AscitesGarcia‐Tsao G. Ascites 2011, 210-233. DOI: 10.1002/9781444341294.ch10.
• Congenital Hepatic Vascular MalformationsGarcia-Tsao G. Congenital Hepatic Vascular Malformations 2011, 213-227. DOI: 10.1007/978-1-4419-8327-5_14.
• Management: Cirrhotic Portal HypertensionLim J, Garcia-Tsao G. Management: Cirrhotic Portal Hypertension 2011, 165-181. DOI: 10.1007/978-1-4419-8327-5_11.
• Spontaneous Bacterial Peritonitis – Prophylaxis and TreatmentWiest R, Garcia-Tsao G. Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment 2011, 28: 65-82. DOI: 10.1159/000318963.
• Vasoconstrictor Therapy for Hepatorenal SyndromeYeo C, Garcia-Tsao G. Vasoconstrictor Therapy for Hepatorenal Syndrome 2011, 28: 149-162. DOI: 10.1159/000318997.
• Classification of Cirrhosis: The Clinical Use of HVPG MeasurementsAlbilllos A, Garcia-Tsao G. Classification of Cirrhosis: The Clinical Use of HVPG Measurements Disease Markers 2011, 31: 121-128. DOI: 10.1155/2011/706032.
• Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial PeritonitisTandon P, Garcia–Tsao G. Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis Clinical Gastroenterology And Hepatology 2010, 9: 260-265. PMID: 21145427, PMCID: PMC3713475, DOI: 10.1016/j.cgh.2010.11.038.
• Hepatic Venous Pressure Gradient, Biopsy or Both?Garcia‐Tsao G. Hepatic Venous Pressure Gradient, Biopsy or Both? 2010, 7-17. DOI: 10.1002/9781444393989.ch1.
• Antibiotic Prophylaxis and Management of Bacterial InfectionsLim J, Tandon P, Garcia-Tsao G. Antibiotic Prophylaxis and Management of Bacterial Infections 2010, 395-410. DOI: 10.1007/978-1-60761-866-9_20.
• Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosisSalerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia‐Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis Liver International 2010, 30: 937-947. PMID: 20492521, DOI: 10.1111/j.1478-3231.2010.02272.x.
• S1918 A Hemodynamic Response to Treatment With Non-Selective Beta-Blockers Protects Against Worsening of Thrombocytopenia in CirrhosisQamar A, Grace N, Groszmann R, Garcia-Tsao G, Bosch J, Burroughs A, Iskandar H, Maurer R, Planas R, Escorsell A, Garcia-Pagan J, Patch D, Matloff D, Makuch R, From P. S1918 A Hemodynamic Response to Treatment With Non-Selective Beta-Blockers Protects Against Worsening of Thrombocytopenia in Cirrhosis Gastroenterology 2010, 138: s-817. DOI: 10.1016/s0016-5085(10)63764-x.
• Sildenafil Has No Effect on Portal Pressure but Lowers Arterial Pressure in Patients With Compensated CirrhosisTandon P, Inayat I, Tal M, Spector M, Shea M, Groszmann RJ, Garcia–Tsao G. Sildenafil Has No Effect on Portal Pressure but Lowers Arterial Pressure in Patients With Compensated Cirrhosis Clinical Gastroenterology And Hepatology 2010, 8: 546-549. PMID: 20144739, PMCID: PMC2879450, DOI: 10.1016/j.cgh.2010.01.017.
• Reply to Qi et al.Garcia-Tsao G. Reply to Qi et al. The American Journal Of Gastroenterology 2010, 105: 472. DOI: 10.1038/ajg.2009.628.
• Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosisGarcia‐Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis Hepatology 2009, 51: 1445-1449. PMID: 20077563, PMCID: PMC2882065, DOI: 10.1002/hep.23478.
• Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner is…Bosch J, Garcia‐Tsao G. Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner is… Hepatology 2009, 50: 674-677. PMID: 19714716, DOI: 10.1002/hep.23164.
• Use of Over-the-Counter Analgesics Is Not Associated With Acute Decompensation in Patients With CirrhosisKhalid SK, Lane J, Navarro V, Garcia–Tsao G. Use of Over-the-Counter Analgesics Is Not Associated With Acute Decompensation in Patients With Cirrhosis Clinical Gastroenterology And Hepatology 2009, 7: 994-999. PMID: 19394441, PMCID: PMC3777825, DOI: 10.1016/j.cgh.2009.04.015.
• Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated CirrhosisQamar AA, Grace ND, Groszmann RJ, Garcia–Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia–Pagan J, Patch D, Matloff DS, Makuch R, Rendon G, Group P. Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis Clinical Gastroenterology And Hepatology 2009, 7: 689-695. PMID: 19281860, PMCID: PMC4545534, DOI: 10.1016/j.cgh.2009.02.021.
• Approach to the Patient with Ascites and its ComplicationsGarcia‐Tsao G. Approach to the Patient with Ascites and its Complications 2009, 103-113. DOI: 10.1002/9781444303414.ch10.
• Vascular disorders of the liverDeLeve LD, Valla D, Garcia‐Tsao G. Vascular disorders of the liver Hepatology 2008, 49: 1729-1764. PMID: 19399912, PMCID: PMC6697263, DOI: 10.1002/hep.22772.
• Ascites and its ComplicationsGarcia‐Tsao G. Ascites and its Complications 2008, 2302-2326. DOI: 10.1002/9781444303254.ch90.
• Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: In search of predictors of significant diseaseGarcia‐Tsao G, Swanson KL. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: In search of predictors of significant disease Hepatology 2008, 48: 1377-1379. PMID: 18972437, DOI: 10.1002/hep.22672.
• Acute kidney injury in cirrhosisGarcia‐Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis Hepatology 2008, 48: 2064-2077. PMID: 19003880, DOI: 10.1002/hep.22605.
• Hepatic Vascular Malformations in Hereditary Hemorrhagic TelangiectasiaKhalid1 S, Garcia-Tsao1 G. Hepatic Vascular Malformations in Hereditary Hemorrhagic Telangiectasia Seminars In Liver Disease 2008, 28: 247-258. PMID: 18814078, DOI: 10.1055/s-0028-1085093.
• Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assayMayo MJ, Parkes J, Adams‐Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia‐Tsao G, Barnes D, Rosenberg WM. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay Hepatology 2008, 48: 1549-1557. PMID: 18846542, PMCID: PMC2597274, DOI: 10.1002/hep.22517.
• Approach to the Patient with Ascites and Its ComplicationsGarcia‐Tsao G. Approach to the Patient with Ascites and Its Complications 2008, 442-466. DOI: 10.1002/9781444300758.ch23.
• Portal hypertension and variceal bleeding—Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single‐topic conferenceGarcia‐Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding—Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single‐topic conference Hepatology 2008, 47: 1764-1772. PMID: 18435460, DOI: 10.1002/hep.22273.
• A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal SyndromeSanyal AJ, Boyer T, Garcia–Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Group T. A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome Gastroenterology 2008, 134: 1360-1368. PMID: 18471513, PMCID: PMC3730280, DOI: 10.1053/j.gastro.2008.02.014.
• Bacterial Infections, Sepsis, and Multiorgan Failure in CirrhosisTandon1 P, Garcia-Tsao2 G. Bacterial Infections, Sepsis, and Multiorgan Failure in Cirrhosis Seminars In Liver Disease 2008, 28: 026-042. PMID: 18293275, DOI: 10.1055/s-2008-1040319.
• ReplyRipoll C, Garcia–Tsao G, Groszmann R. Reply Gastroenterology 2008, 134: 641-642. DOI: 10.1053/j.gastro.2007.12.006.
• 317 PROGNOSTIC INDICATORS OF SURVIVAL IN COMPENSATED AND DECOMPENSATED STAGES OF LIVER CIRRHOSIS: VALIDATION OF A 4-STAGE CLASSIFICATIONZipprich A, Dollinger M, Garcia-Tsao G, Rogowski S, Fleig W. 317 PROGNOSTIC INDICATORS OF SURVIVAL IN COMPENSATED AND DECOMPENSATED STAGES OF LIVER CIRRHOSIS: VALIDATION OF A 4-STAGE CLASSIFICATION Journal Of Hepatology 2008, 48: s125-s126. DOI: 10.1016/s0168-8278(08)60319-0.
• Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosisQamar AA, Grace ND, Groszmann RJ, Garcia‐Tsao G, Bosch J, Burroughs AK, Maurer R, Planas R, Escorsell A, Garcia‐Pagan J, Patch D, Matloff DS, Makuch R. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis Hepatology 2007, 47: 153-159. PMID: 18161700, DOI: 10.1002/hep.21941.
• A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhageLongacre AV, Imaeda A, Garcia‐Tsao G, Fraenkel L. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage Hepatology 2007, 47: 169-176. PMID: 17935182, PMCID: PMC2674014, DOI: 10.1002/hep.21945.
• Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United StatesPeters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia‐Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States Hepatology 2007, 46: 769-775. PMID: 17654740, PMCID: PMC4167731, DOI: 10.1002/hep.21759.
• Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisGarcia‐Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis Hepatology 2007, 46: 922-938. PMID: 17879356, DOI: 10.1002/hep.21907.
• Congenital Vascular MalformationsGarcía‐Tsao G. Congenital Vascular Malformations 2007, 1418-1423. DOI: 10.1002/9780470691861.ch17d.
• Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated CirrhosisRipoll C, Groszmann R, Garcia–Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia–Pagan J, Makuch R, Patch D, Matloff DS, Bosch J, Group P. Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis Gastroenterology 2007, 133: 481-488. PMID: 17681169, DOI: 10.1053/j.gastro.2007.05.024.
• Model for end‐stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasiaGarcia‐Tsao G, Gish RG, Punch J. Model for end‐stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia Liver Transplantation 2006, 12: s108-s109. PMID: 17123286, DOI: 10.1002/lt.20978.
• ReplyGroszmann R, Garcia-Tsao G. Reply Gastroenterology 2006, 131: 676. DOI: 10.1053/j.gastro.2006.06.054.
• Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Internal Medicine 2006, 5: 399-407. DOI: 10.1097/01.mog.0000218962.93806.9a.
• Session 2: Predictive Models in Portal HypertensionGarcia‐Tsao G, D'Amico G, Abraldes J, Schepis F, Merli M, Kim W, Christensen E. Session 2: Predictive Models in Portal Hypertension 2006, 47-102. DOI: 10.1002/9780470988831.ch4.
• Chapter 19 AscitesGarcia-Tsao G. Chapter 19 Ascites 2006, 333-346. DOI: 10.1016/b978-1-4160-3258-8.50024-3.
• Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia‐Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders† Journal Of Viral Hepatitis 2005, 13: 235-241. PMID: 16611189, DOI: 10.1111/j.1365-2893.2005.00681.x.
• Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosisCombes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL, Rosoff L, Garcia‐Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis Hepatology 2005, 42: 1184-1193. PMID: 16250039, DOI: 10.1002/hep.20897.
• Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in CirrhosisGarcia‐Tsao G. Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in Cirrhosis 2005, 251-259. DOI: 10.1002/9780470987476.ch20.
• Sepsis in cirrhosis: report on the 7th meeting of the International Ascites ClubWong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club Gut 2005, 54: 718. PMID: 15831923, PMCID: PMC1774473, DOI: 10.1136/gut.2004.038679.
• Bacterial translocation (BT) in cirrhosisWiest R, Garcia‐Tsao G. Bacterial translocation (BT) in cirrhosis Hepatology 2005, 41: 422-433. PMID: 15723320, DOI: 10.1002/hep.20632.
• AscitesKbalid S, Garcia-Tsao G. Ascites 2005, 285-299. DOI: 10.1007/978-1-59259-885-4_19.
• Treatment of acute variceal bleeding: general management and prevention of infectionsGarcia-Tsao G. Treatment of acute variceal bleeding: general management and prevention of infections 2004, 233-240. DOI: 10.1007/978-94-007-1042-9_25.
• Bacterial translocation up‐regulates GTP‐cyclohydrolase I in mesenteric vasculature of cirrhotic ratsWiest R, Cadelina G, Milstien S, McCuskey RS, Garcia‐Tsao G, Groszmann RJ. Bacterial translocation up‐regulates GTP‐cyclohydrolase I in mesenteric vasculature of cirrhotic rats Hepatology 2003, 38: 1508-1515. PMID: 14647062, DOI: 10.1016/j.hep.2003.09.039.
• Effect of Lactobacillus-Fermented Diets on Bacterial Translocation and Intestinal Flora in Experimental Prehepatic Portal HypertensionWiest R, Chen F, Cadelina G, Groszmann R, Garcia-Tsao G. Effect of Lactobacillus-Fermented Diets on Bacterial Translocation and Intestinal Flora in Experimental Prehepatic Portal Hypertension Digestive Diseases And Sciences 2003, 48: 1136-1141. PMID: 12822876, DOI: 10.1023/a:1023729115659.
• Comparison of hepatitis C (HCV) treatment patterns in patients with and without mental illness (MI) and/or substance abuse (SA)Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Semyak M, Wongcharatrawee S, Garcia-Tsao G. Comparison of hepatitis C (HCV) treatment patterns in patients with and without mental illness (MI) and/or substance abuse (SA) Gastroenterology 2003, 124: a781. DOI: 10.1016/s0016-5085(03)83945-8.
• 103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factorGroszmann R, Garcia-Tsao G, Makuch R, Bosch J, Escorsel A, Garcia-Pagan J, Grace N, Matloff D, Burroughs A, Patch D. 103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor Hepatology 2003, 38: 206. DOI: 10.1016/s0270-9139(03)80146-5.
• 553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis?Nagula S, Jain D, Groszmann R, Garcia-Tsao G. 553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis? Hepatology 2003, 38: 426-427. DOI: 10.1016/s0270-9139(03)80595-5.
• 1127 Do over-the-counter analgesics contribute to decompensation of cirrhosis? — a prospective studyKhalid S, Addesa J, Navarro V, Garcia-Tsao G. 1127 Do over-the-counter analgesics contribute to decompensation of cirrhosis? — a prospective study Hepatology 2003, 38: 698-699. DOI: 10.1016/s0270-9139(03)81165-5.
• Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosisGinès P, Uriz J, Calahorra B, Garcia–Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J, Cirrhosis F. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis Gastroenterology 2002, 123: 1839-1847. PMID: 12454841, DOI: 10.1053/gast.2002.37073.
• Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?Burroughs A, Groszmann R, Bosch J, Grace N, Garcia-Tsao G, Patch D, Garcia-Pagan J, Dagher L. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002, 50: 425. PMID: 11839726, PMCID: PMC1773121, DOI: 10.1136/gut.50.3.425.
• Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment?Abraczinskas D, Ookubo R, Grace N, Groszmann R, Bosch J, Garcia‐Tsao G, Richardson C, Matloff D, Rodés J, Conn H. Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment? Hepatology 2001, 34: 1096-1102. PMID: 11731997, DOI: 10.1053/jhep.2001.29305.
• CLINICAL MANAGEMENT OF ASCITES AND ITS COMPLICATIONSWongcharatrawee S, Garcia-Tsao G. CLINICAL MANAGEMENT OF ASCITES AND ITS COMPLICATIONS Clinics In Liver Disease 2001, 5: 833-850. PMID: 11565143, DOI: 10.1016/s1089-3261(05)70194-x.
• Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Gastroenterology 2001, 17: 281-290. PMID: 17031170, DOI: 10.1097/00001574-200105000-00012.
• Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitisGarcia–Tsao G. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis Gastroenterology 2001, 120: 726-748. PMID: 11179247, DOI: 10.1053/gast.2001.22580.
• Treatment of refractory ascites: Tips or taps?Garcia‐Tsao G. Treatment of refractory ascites: Tips or taps? Hepatology 2001, 33: 477-479. PMID: 11172354, DOI: 10.1053/jhep.2001.0330477.
• Session 1 ‒ Definition of Key Events: Lets's Try AgainBurroughs A, Bosch J, Garcia‐Tsao G, Henderson J, Laine L, Nevens F, Riggio O. Session 1 ‒ Definition of Key Events: Lets's Try Again 2001, 13-21. DOI: 10.1002/9780470760154.ch2.
• Session 2 ‒ Diagnosis of Portal Hypertension: How and WhenD'Amico G, Garcia‐Tsao G, Cales P, Escorsell A, Nevens F, Cestari R, Caletti G, Zoli M. Session 2 ‒ Diagnosis of Portal Hypertension: How and When 2001, 36-64. DOI: 10.1002/9780470760154.ch4.
• Session 8 ‒ Complications in the Medical Treatment of Portal HypertensionBolognesi M, Balducci G, Garcia‐Tsao G, Gatta A, Gines P, Merli M, Rodes J, Stiegmann G. Session 8 ‒ Complications in the Medical Treatment of Portal Hypertension 2001, 180-203. DOI: 10.1002/9780470760154.ch12.
• Liver Disease in Patients with Hereditary Hemorrhagic TelangiectasiaGarcia-Tsao G, Korzenik J, Young L, Henderson K, Jain D, Byrd B, Pollak J, White R. Liver Disease in Patients with Hereditary Hemorrhagic Telangiectasia New England Journal Of Medicine 2000, 343: 931-936. PMID: 11006369, DOI: 10.1056/nejm200009283431305.
• Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Gastroenterology 2000, 16: 282-289. PMID: 17023887, DOI: 10.1097/00001574-200005000-00012.
• Ultrasound parameters in the prediction of clinically significant portal hypertension (CS-PHT) in compensated cirrhosisAyala J, Zalwin M, Taylor C, Bosch J, Groszmann R, Garcia-Tsao G. Ultrasound parameters in the prediction of clinically significant portal hypertension (CS-PHT) in compensated cirrhosis Gastroenterology 2000, 118: a968. DOI: 10.1016/s0016-5085(00)86014-x.
• Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus documentRimola A, García-Tsao G, Navasa M, Piddock L, Planas R, Bernard B, Inadomi J, Club T. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document Journal Of Hepatology 2000, 32: 142-153. PMID: 10673079, DOI: 10.1016/s0168-8278(00)80201-9.
• Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractilityWiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann R. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility Journal Of Clinical Investigation 1999, 104: 1223-1233. PMID: 10545521, PMCID: PMC409820, DOI: 10.1172/jci7458.
• The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosisCombes B, Markin R, Wheeler D, Rubin R, West A, Mills A, Eigenbrodt E, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Carithers R. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis Hepatology 1999, 30: 602-605. PMID: 10462363, PMCID: PMC3935822, DOI: 10.1002/hep.510300315.
• Identifying new risk factors for spontaneous bacterial peritonitis: How important is it?Garcia–Tsao G. Identifying new risk factors for spontaneous bacterial peritonitis: How important is it? Gastroenterology 1999, 117: 495-499. PMID: 10419933, DOI: 10.1053/gast.1999.0029900495.
• Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acidCombes B, Carithers R, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Risser R, Rossi S, Hofmann A. Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid Hepatology 1999, 29: 1649-1654. PMID: 10347103, PMCID: PMC4004074, DOI: 10.1002/hep.510290618.
• Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Gastroenterology 1999, 15: 260-269. PMID: 17023954, DOI: 10.1097/00001574-199905000-00012.
• Low‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurementsSteinlauf A, Garcia‐Tsao G, Zakko M, Dickey K, Gupta T, Groszmann R. Low‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements Hepatology 1999, 29: 1070-1073. PMID: 10094948, DOI: 10.1002/hep.510290421.
• Portal hypertension and variceal bleeding: An AASLD single topic symposiumGrace N, Groszmann R, Garcia‐Tsao G, Burroughs A, Pagliaro L, Makuch R, Bosch J, Stiegmann G, Henderson J, de Franchis R, Wagner J, Conn H, Rodes J. Portal hypertension and variceal bleeding: An AASLD single topic symposium Hepatology 1998, 28: 868-880. PMID: 9731585, DOI: 10.1002/hep.510280339.
• The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitisGarcia‐Tsao G, Angulo P, Garcia J, Groszmann R, Cadelina G. The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis Hepatology 1998, 28: 17-21. PMID: 9657091, DOI: 10.1002/hep.510280104.
• Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Gastroenterology 1998, 14: 256-264. DOI: 10.1097/00001574-199805000-00012.
• Viral RNA in duodenal bile of cirrhotic patients with chronic hepatitis C.Kuan S, Garcia-Tsao G, Cartun R, Emanuel J, West A. Viral RNA in duodenal bile of cirrhotic patients with chronic hepatitis C. Archives Of Pathology & Laboratory Medicine 1997, 121: 847-52. PMID: 9278613.
• The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varicesEscorsell A, Ferayorni L, Bosch J, Garcia-Pagan J, Garcia-Tsao G, Grace N, Rodes J, Groszmann R. The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices Gastroenterology 1997, 112: 2012-2016. PMID: 9178694, DOI: 10.1053/gast.1997.v112.pm9178694.
• Further evidence in favor of pharmacological portal pressure reduction in the prevention of variceal hemorrhage.García-Tsao G. Further evidence in favor of pharmacological portal pressure reduction in the prevention of variceal hemorrhage. Gastroenterology 1997, 112: 1770-1. PMID: 9136864.
• Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Gastroenterology 1997, 13: 263-270. DOI: 10.1097/00001574-199705000-00013.
• Portal hypertensionGarcia-Tsao, G. Portal hypertension. Curr Opinion Gastro 13:263-270, 1997.
• Treatment of spontaneous bacterial peritonitis with oral ofloxacin: inpatient or outpatient therapy?García-Tsao G. Treatment of spontaneous bacterial peritonitis with oral ofloxacin: inpatient or outpatient therapy? Gastroenterology 1996, 111: 1147-50. PMID: 8831614.
• Gastroesophageal varices hemorrhage: non-surgical treatment.García-Tsao G. Gastroesophageal varices hemorrhage: non-surgical treatment. Revista De Gastroenterología De México 1996, 61: s87-9. PMID: 9102789.
• A randomized double-blind, placebo-controlled trial ursodeoxycholic acid in primary biliary cirrhosisCombes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized double-blind, placebo-controlled trial ursodeoxycholic acid in primary biliary cirrhosis European Journal Of Gastroenterology & Hepatology 1995, 7: 1132. DOI: 10.1097/00042737-199511000-00024.
• A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosisCombes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia‐Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 1995, 22: 759-766. PMID: 7657280, DOI: 10.1002/hep.1840220311.
• A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosisCombes B, Carithers R, Maddrey W, Lin D, Mcdonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 1995, 22: 759-766. DOI: 10.1016/0270-9139(95)90294-5.
• Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascitesGarcia-Tsao G, Lee F, Barden G, Cartun R, West A. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites Gastroenterology 1995, 108: 1835-1841. PMID: 7768390, DOI: 10.1016/0016-5085(95)90147-7.
• Detection of hepatitis C virus RNA by RT-PCR in the bile of patients with hepatitis CKuan S, Emanuel J, Howe C, West A, Garcia-Tsao G. Detection of hepatitis C virus RNA by RT-PCR in the bile of patients with hepatitis C Gastroenterology 1995, 108: a1103. DOI: 10.1016/0016-5085(95)28715-9.
• Variceal HemorrhageNavarro V, Garcia-Tsao G. Variceal Hemorrhage Critical Care Clinics 1995, 11: 391-414. PMID: 7788538, DOI: 10.1016/s0749-0704(18)30073-3.
• Cirrhotic ascites: pathogenesis and management.Garcia-Tsao G. Cirrhotic ascites: pathogenesis and management. The Gastroenterologist 1995, 3: 41-54. PMID: 7743121.
• Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-doppler studyBuonamico P, Sabba C, Garcia-Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen J, Lerner E, Taylor K, Albano O, Groszmann R. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-doppler study Hepatology 1995, 21: 134-139. DOI: 10.1016/0270-9139(95)90420-4.
• Treatment of chronic hepatitis C.García-Tsao G. Treatment of chronic hepatitis C. Revista De Gastroenterología De México 1995, 60: s52-3. PMID: 8948779.
• Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler studyBuonamico P, Sabbá C, Garcia‐Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen J, Lerner E, Taylor K, Albano O, Groszmann R. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler study Hepatology 1995, 21: 134-139. PMID: 7806146, DOI: 10.1002/hep.1840210123.
• A Comparative Clinical Study of Idiopathic Portal Hypertension, Extrahepatic Portal Vein Thrombosis, and CirrhosisOrozco H, Takahashi T, Garcia-Tsao G, Mercado M, Prado E, Nava R. A Comparative Clinical Study of Idiopathic Portal Hypertension, Extrahepatic Portal Vein Thrombosis, and Cirrhosis Journal Of Clinical Gastroenterology 1994, 19: 217-221. PMID: 7806833, DOI: 10.1097/00004836-199410000-00010.
• Bacterial translocation in acute and chronic portal hypertensionQuigley E, Garcia‐Tsao G. Bacterial translocation in acute and chronic portal hypertension Hepatology 1994, 20: 264-266. PMID: 8020899, DOI: 10.1002/hep.1840200145.
• Bacterial translocation in acute and chronic portal hypertensionGarcia‐Tsao G, Albillos A, Barden G, West A. Bacterial translocation in acute and chronic portal hypertension Hepatology 1993, 17: 1081-1085. PMID: 8514258, DOI: 10.1002/hep.1840170622.
• Outpatient liver biopsy: how safe is it?Garcia-Tsao G, Boyer J. Outpatient liver biopsy: how safe is it? Annals Of Internal Medicine 1993, 118: 150-3. PMID: 8416312, DOI: 10.7326/0003-4819-118-2-199301150-00013.
• Elective treatment of bleeding varices with the Sugiura operation over 10 yearsOrozco H, Mercado M, Takahashi T, Hernández-Ortiz J, Capellán^S J, Garcia-Tsao G. Elective treatment of bleeding varices with the Sugiura operation over 10 years The American Journal Of Surgery 1992, 163: 585-589. PMID: 1595838, DOI: 10.1016/0002-9610(92)90562-6.
• Bacillary peliosis hepatis as a cause of acute anemia in a patient with the acquired immunodeficiency syndromeGarcia-Tsao G, Panzini L, Yoselevitz M, West A. Bacillary peliosis hepatis as a cause of acute anemia in a patient with the acquired immunodeficiency syndrome Gastroenterology 1992, 102: 1065-1070. PMID: 1537498, DOI: 10.1016/0016-5085(92)90200-i.
• SPONTANEOUS BACTERIAL PERITONITISGarcia-Tsao G. SPONTANEOUS BACTERIAL PERITONITIS Gastroenterology Clinics Of North America 1992, 21: 257-275. PMID: 1568776, DOI: 10.1016/s0889-8553(21)00617-8.
• ReplyGroszmann R, Garcia-Tsao G, Grace N, Bosch J. Reply Gastroenterology 1991, 101: 1760-1761. DOI: 10.1016/0016-5085(91)90443-o.
• ReplyGroszmann R, Lerner E, Bosch J, Garcia-Tsao G, Grace N. Reply Gastroenterology 1991, 101: 591-592. DOI: 10.1016/0016-5085(91)90052-m.
• The Sugiura procedure for patients with hemorrhagic portal hypertension secondary to extrahepatic portal vein thrombosis.Orozco H, Takahashi T, Mercado M, Garcia-Tsao G, Hernandez-Ortiz J. The Sugiura procedure for patients with hemorrhagic portal hypertension secondary to extrahepatic portal vein thrombosis. Journal Of The American College Of Surgeons 1991, 173: 45-8. PMID: 1866670.
• Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trialConn H, Grace N, Bosch J, Groszmann R, Rodés J, Wright S, Matloff D, Garcia‐Tsao G, Fisher R, Navasa M, Drewniak S, Atterbury C, Bordas J, Lerner E, Bramante C. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial Hepatology 1991, 13: 902-912. PMID: 2029994, DOI: 10.1002/hep.1840130517.
• Treatment of ascites with A single total paracentesisGarcia-Tsao G. Treatment of ascites with A single total paracentesis Hepatology 1991, 13: 1005-1007. PMID: 2029984, DOI: 10.1002/hep.1840130534.
• Partial hepatectomy for Caroli's syndrome. Report of two patients with long-term follow-up.Orozco H, Takahashi T, Garcia-Tsao G, Mercado M, Quiroz F, Hernandez-Cendejas A. Partial hepatectomy for Caroli's syndrome. Report of two patients with long-term follow-up. Hepatogastroenterology 1991, 38: 33-5. PMID: 2026386.
• Idiopathic portal hypertension.Orozco H, Takahashi T, García-Tsao G, Mercado M, Diliz H, Hernández-Ortiz J. Idiopathic portal hypertension. Revista De Investigación Clínica 1991, 43: 80-6. PMID: 1866503.
• Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhageGroszmann R, Bosch J, Grace N, Conn H, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M, Rofe S, Patrick M, Lerner E. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage Gastroenterology 1990, 99: 1401-1407. PMID: 2210246, DOI: 10.1016/0016-5085(90)91168-6.
• Postoperative portal vein obstruction in patients with idiopathic portal hypertension.Orozco H, Takahashi T, Mercado M, Garcia-Tsao G, Gonzalez-Lopez-Lira A, Hernandez-Ortiz J. Postoperative portal vein obstruction in patients with idiopathic portal hypertension. Journal Of Clinical Gastroenterology 1990, 12: 607. PMID: 2230012, DOI: 10.1097/00004836-199010000-00030.
• Role of the distal splenorenal shunt in management of variceal bleeding in Latin AmericaOrozco H, Mercado M, Takahashi T, García-Tsao G, Guevara L, Ortíz J, Hernández-Cendejas A, Tielve M. Role of the distal splenorenal shunt in management of variceal bleeding in Latin America The American Journal Of Surgery 1990, 160: 86-89. PMID: 2368881, DOI: 10.1016/s0002-9610(05)80874-8.
• Selective portal-systemic shunts for bleeding portal hypertension.Orozco H, Mercado M, Takahashi T, García-Tsao G, Guevara L, Hernandez-Ortiz J, Tielve M. Selective portal-systemic shunts for bleeding portal hypertension. Revista De Investigación Clínica 1990, 42 Suppl: 165-9. PMID: 19256158.
• Surgical treatment of hemorrhage of esophageal varices secondary to thrombosis of the portal vein.Orozco-Zepeda H, Takahashi T, Angel Mercado M, García-Tsao G, Hernández-Ortiz J. Surgical treatment of hemorrhage of esophageal varices secondary to thrombosis of the portal vein. Revista De Gastroenterología De México 1990, 55: 215-9. PMID: 2091189.
• Usefulness of the histologic and microbiologic study of liver biopsy in the diagnosis of fever of unknown origin.Páez-Rodríguez O, García-Tsao G, Sifuentes J. Usefulness of the histologic and microbiologic study of liver biopsy in the diagnosis of fever of unknown origin. Revista De Gastroenterología De México 1990, 55: 1-6. PMID: 2291060.
• Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trialBosch J, Groszmann R, García‐Pagán J, Terés J, García‐Tsao G, Navasa M, Mas A, Rodés J. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trial Hepatology 1989, 10: 962-968. PMID: 2511136, DOI: 10.1002/hep.1840100612.
• Idiopathic portal hypertension and protein C deficiency to the editorOkuda K, Orozco H, Garcia‐Tsao G, Takahashi T. Idiopathic portal hypertension and protein C deficiency to the editor Hepatology 1989, 10: 903-903. PMID: 2807176, DOI: 10.1002/hep.1840100534.
• Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis.Bobadilla M, Sifuentes J, Garcia-Tsao G. Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis. Journal Of Clinical Microbiology 1989, 27: 2145-7. PMID: 2685014, PMCID: PMC266981, DOI: 10.1128/jcm.27.10.2145-2147.1989.
• Colchicine treatment of cirrhosis: AnswersKershenobich D, Vargas F, Garcia‐Tsao G, Tamayo R, Gent M, Rojkind M. Colchicine treatment of cirrhosis: Answers Hepatology 1989, 9: 656-657. PMID: 2925170, DOI: 10.1002/hep.1840090425.
• Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patientsVorobioff J, Garcia‐Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio R, Hernandez‐Ortiz J. Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients Hepatology 1989, 9: 88-91. PMID: 2908873, DOI: 10.1002/hep.1840090114.
• Hepatic fibropolycystic disease in Mexico. Study of 82 cases.Torres-Barrera G, García-Tsao G, Quiroz F, Ferrari. Hepatic fibropolycystic disease in Mexico. Study of 82 cases. Revista De Investigación Clínica 1989, 41: 45-52. PMID: 2727432.
• Distal splenorenal vs. portal‐systemic shunts after hemorrhage from varices: A randomized controlled trialGrace N, Conn H, Resnick R, Groszmann R, Atterbury C, Wright S, Gusberg R, Vollman R, Garcia‐Tsao G, Fisher R, O'Hara E, McDermott W, Maselli J, Widrich W, Matloff D, Horst D, Banks N, Alberts J. Distal splenorenal vs. portal‐systemic shunts after hemorrhage from varices: A randomized controlled trial Hepatology 1988, 8: 1475-1481. PMID: 3056820, DOI: 10.1002/hep.1840080602.
• Deficiency of protein C in patients with portal vein thrombosisOrozco H, Guraieb E, Takahashi T, Garcia‐Tsao G, Hurtado R, Anaya R, Ruiz‐Arguelles G, Hernandez‐Ortiz J, Casillas M, Guevara L. Deficiency of protein C in patients with portal vein thrombosis Hepatology 1988, 8: 1110-1111. PMID: 3262079, DOI: 10.1002/hep.1840080522.
• Colchicine in the Treatment of Cirrhosis of the LiverKershenobich D, Vargas F, Garcia-Tsao G, Tamayo R, Gent M, Rojkind M. Colchicine in the Treatment of Cirrhosis of the Liver New England Journal Of Medicine 1988, 318: 1709-1713. PMID: 3287167, DOI: 10.1056/nejm198806303182602.
• Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis Pharmacokinetic-hemodynamic interactionsBlei A, Garcia-Tsao G, Groszmann R, Kahrilas P, Ganger D, Morse S, Fung H. Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis Pharmacokinetic-hemodynamic interactions Gastroenterology 1987, 93: 576-583. PMID: 3301517, DOI: 10.1016/0016-5085(87)90921-8.
• Portal hemodynamics during nitroglycerin administration in cirrhotic patientsGarcia‐Tsao G, Groszmann R. Portal hemodynamics during nitroglycerin administration in cirrhotic patients Hepatology 1987, 7: 805-809. PMID: 3115881, DOI: 10.1002/hep.1840070502.
• Quantitative US attenuation in normal liver and in patients with diffuse liver disease: importance of fat.Taylor K, Riely C, Hammers L, Flax S, Weltin G, Garcia-Tsao G, Conn H, Kuc R, Barwick K. Quantitative US attenuation in normal liver and in patients with diffuse liver disease: importance of fat. Radiology 1986, 160: 65-71. PMID: 3520657, DOI: 10.1148/radiology.160.1.3520657.
• Short‐term effects of propranolol on portal venous pressureGarcia‐Tsao G, Grace N, Groszmann R, Conn H, Bermann M, Patrick M, Morse S, Alberts J. Short‐term effects of propranolol on portal venous pressure Hepatology 1986, 6: 101-106. PMID: 3943775, DOI: 10.1002/hep.1840060119.
• Portal pressure, presence of gastroesophageal varices and variceal bleedingGarcia‐Tsao G, Groszmann R, Fisher R, Conn H, Atterbury C, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding Hepatology 1985, 5: 419-424. PMID: 3873388, DOI: 10.1002/hep.1840050313.
• The diagnosis of bacterial peritonitis: Comparison of pH, lactate concentration and leukocyte countGarcia‐Tsao G, Conn H, Lerner E. The diagnosis of bacterial peritonitis: Comparison of pH, lactate concentration and leukocyte count Hepatology 1985, 5: 91-96. PMID: 3967868, DOI: 10.1002/hep.1840050119.
• A study with quinfamide in the treatment of chronic amebiasis in adults.Guevara L, Garcia Tsao G, Uscanga L. A study with quinfamide in the treatment of chronic amebiasis in adults. Clinical Therapeutics 1983, 6: 43-6. PMID: 6673830.
• Early detection of alcoholism in a hospital population (author's transl).de la Fuente J, Gutiérrez L, Rivero F, García Tsao G, Rojkind M, Kershenobich D. Early detection of alcoholism in a hospital population (author's transl). Revista De Investigación Clínica 1982, 34: 1-6. PMID: 7089394.
• Relationship between blood lactic acid and serum proline in alcoholic liver cirrhosisKershenobich D, García-Tsao G, Saldana S, Rojkind M. Relationship between blood lactic acid and serum proline in alcoholic liver cirrhosis Gastroenterology 1981, 80: 1012-1015. PMID: 7202961, DOI: 10.1016/0016-5085(81)90074-3.